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ABSTRACT
IDENTIFICATION AND BIOCHEMICAL CHARACTERIZATION OF THE

CHLAMYDIA TRACHOMA TIS TYPE III SECRETION CHAPERONE, SLCl,
AND ITS ROLE IN THE TRANSLOCATION OF THE INVASIONASSOCIATED EFFECTOR T ARP

Amanda Brinkworth
May 2011
Chlamydia trachomatis is an obligate intracellular pathogen that utilizes a type III

secretion system to enter mammalian cells and establish an intracellular niche. TARP,
the translocated

~ctin

recruitment 12rotein, is a chlamydial invasion protein known to be

type III secreted by the metabolically inert elementary body upon docking to the
mammalian cell surface. Because immediate secretion of TARP into host cells is
necessary for entry, I hypothesized that a chlamydial chaperone binds to TARP and
facilitates its translocation through the type III secretion apparatus. Most effectorbinding type III secretion chaperones are small (14-18 kDa), have an acidic pI, and share
a specific secondary structure of alternating alpha-helices (a) and beta-sheets

(~).

Typically, type III secretion chaperones dimerize and interact with their effectors as a
complex of two molecules of chaperone to one effector molecule. Only 3 Chlamydia
trachomatis proteins have been identified in EB' s that are predicted to be putative

chlamydial type III effector chaperones. These are CT043, CT663, and CT088, which I
have designated as SIc 1, SIc2, and Scc 1, respectively. These chaperones were tested for
their interaction with the N-terminal200 amino acids ofTARP (HIS6_TARpl-200) by co-

v

immunoprecipitation. HIS 6 - TARp l-200 interacted specifically with SlcI, but not Scc1 or
Slc2. This interaction was enhanced by coexpression of the recombinant proteins. To
confirm this interaction and rule out the possibility of Slc 1 heterodimerization enhancing
the interaction with TARP, I employed a 2-hybrid system to test for TARP: chaperone
and chaperone:chaperone interactions. I confirmed the specific interaction between
CyalS-TARp l-200 and Cya2S-Slc 1. I was also able to detect SIc1 interaction with itself as
well as confirm a few other previously described chaperone-chaperone interactions.
Analysis by crosslinking and gel filtration chromatography indicated that Slc 1 forms a
stable dimer in solution. Complexes of the Slci chaperone dimer with TARP in a 2:1
stoichiometry were detected following purification from co-expressing bacteria, but not
following addition of singly purified species. Expression ofbeta-Iactamase fused to
TARp l-200 by the heterologous system Yersinia enterocolitica allowed for secretion of
TARP into type-III inducing media (low calcium). Furthermore I was able to detect
SIc I-dependent translocation of TARP into HeLa cells via the heterologous type III
secretion system of Y enterocolitica, and also by the SPI-2 system of Salmonella

enterica serovar typhimurium.
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CHAPTER I
INTRODUCTION

Epidemiology
A myriad of diseases are caused by pathogenic Chlamydia species that can
efficiently invade human mucosal epithelial cells. Genital infections of the superficial
mucosal epithelium in the endocervix or urethra by serovars D-K can result in cervicitis,
urethritis, endometritis, salpingitis, and proctitis. LGVl-3 of C. trachomatis are
responsible for invasive genital infections that result in lymphogranuloma venereum, and
serovars A-C are responsible for ocular infections that can result in blinding trachoma.
Lung infections with C. pneumoniae or C.psittaci can result in mild upper respiratory or
life-threatening pneumoniae, respectively. Chlamydial infections are also endemic to
koalas, guinea pigs, mice, sheep, and cattle.
Chlamydia is the most common bacterial sexually transmitted disease in the
United States. Most Chlamydia infections are asymptomatic, allowing the bacteria to
persist in the genital tract until it is cleared naturally by the host immune system. In a
small fraction of infected females, long-term complications such as pelvic inflammatory
disease (PID), ectopic pregnancy, and tubal infertility occur[l]. An extensive survey of
Chlamydia genital infections in 2007 was reported by the Center for Disease Control
(CDC) and they estimated over 1.1 million infections in the U.S. Their most convincing
findings were from the screening of the National Job Training applicants that reported
1

infection rates of 13.2% of females and 7.2% of males aged 16-24 year olds Were
positive for C. trachomatis infections[2]. Furthermore the World Health Organization
has estimated over 90 million cases of C. trachomatis infection worldwide[3], with
serovars D, E, and F being the most prevalent[4, 5].
C. trachomatis is also the causative agent of blinding trachoma that accounts for

16% of blindness worldwide. Ocular infection mainly affects young children (0-4 yrs
old) and is cleared without complications within 2-4 weeks. However familial transition
to adults can result in serious scarring of the tarsal conjunctiva, inversion of the eyelid,
and corneal scarring due to scratching by the in-turned eyelashes. Without treatment,
continued irritation by chlamydial antigens will lead to corneal opacity and eventually
blindness[6]. Trachoma is mainly a disease endemic to poverty-stricken villages with
little access to clean water and medicine.
The World Health Organization currently funds a campaign to eradicate blinding
trachoma by 2020 that utilizes the SAFE strategy (.s.urgery, Antibiotic treatment, facial
cleanliness, and Environmental improvement)[7]. Some advanced ocular infections
require eyelid surgery in addition to antibiotic treatment to prevent blindness. Treatment
with tetracycline derivatives (doxycycline) or macrolides (erythromycin, azithromycin) is
sufficient to clear up most C. trachomatis infections. Mass treatment with antibiotics has
been proposed to eradicate trachoma within specific communities, but evidence of
pneumococcal resistance to these antibiotics has emerged as a major barrier to mass
treatment strategies[8].
C. pneumoniae is responsible for 10% of mild upper respiratory infections. It has

been estimated that 80% of people will have had C. pneumoniae infection in their

2

lifetime[9]. C. pneumoniae has also been found in the joints and in atherosclerotic
plaques, associating the bacterium with chronic inflammatory diseases as well[l 0].

Chlamydia pathogenesis

The ability of Chlamydia trachomatis to cause damage to human tissues is a
consequence of the host immune response to infection. Clearance of C. trachomatis
genital infections involves a combination of innate and cellular immune responses[ll,
12] The housekeeping gene, heat-shock protein 70 (Hsp70), from Chlamydia species is
recognized by host cell toll-like receptors TLR2 in cooperation with CD14 to induce
secretion of the pro-inflammatory cytokine IL-8 (interleukin-8)[13]. Initial infection of
human epithelial cells results in the release of pro-inflammatory cytokines such as IL-l p,
IL-6, GM-CSF (granulocyte-macrophage colony stimulating factor) and TNF (tumor
necrosis factor) that attract monocytes, natural killer cells and neutrophils, as well as in
releasing tissue-damaging matrix-metalloproteases (MMPs)[l, 13]. These recruited cells
further release damaging MMP's, elastase, and secrete IFN-y (interferon-gamma) to drive
a Thl-like CD4+ T-cell response. Further mediators of cellular immunity (CD8+ T-cells,
B cells, and plasma cells) are recruited to the site of infection and secrete IFN-y which
activates IDO (indoleamine-2,3-dioxygenase) and subsequently blocks synthesis of
tryptophan in RBs [1, 12].
Treatment ofRB's with IFN-y, Penicillin, or nutrient or iron starvation in cell
culture induces a "persistent" non-dividing, but transcriptionally active state. Under
these conditions the RBs become enlarged while persisting as an "abberant" RB that can
survive inside the host cell for extended periods of time. The fact that these RB' s can be
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recovered from their persistent state and continue their developmental cycle upon
removal of the persistence-inducing stimuli hints at possible role for developmental
persistence in long-term "silent" chlamydial infections[14].
Decreased organismalload and decreased duration of repeat Chlamydia
trachomatis genital infections indicate the induction of adaptive immunity [9, 15, 16].
Interestingly, repeat infections are common and more likely to result in long-term
complications indicating that any acquired immunity is incomplete [17]. Host factors
such as HLA-DR alleles and IL-1 0 promoter polymorphisms are also associated with
clearance of the pathogen by influencing the ability of the infected persons to mount an
effective Thl immune-response[18].
In a minority of infections, the host immune response induces fibrosis and
scarring of the fallopian tubes that are responsible for tubal infertility and ectopic
pregnancy[l, 11]. However, it is still unclear which immune cells are responsible for
infection-associated morbidity. Several studies have identified reduced IFN-y production
by CD4+ T-cells and Peripheral Blood Mononuclear Cells (PBMC's) as an indicator of
tissue damage and long-term sequelae.[19-21].
The challenge of designing a vaccine for immunization against Chlamydia
trachomatis would be to initiate a bacteria-clearing Th1-response while avoiding a tissuedestructive inflammatory response in individuals with previous Chlamydia infections[ll,
16]. In fact, a dead-whole cell vaccine against ocular Chlamydia trachomatis infections
was administered in the 1960's, which was effective in some individuals, while damaging
to those who were re-infected[ 16]. Furthermore, an ideal vaccine would integrate

4

chlamydial antigens that would elicit an effective immune response against all pathogenic

Chlamydia species.

Adaptation ofpathogenic Chlamydia to their mammalian hosts
Comparison of ribosomal RNA from Chlamydiae with that of other modem
prokaryotes indicates a divergence of Chlamydiae from Proteobacteria and other
prokaryotes nearly 2 billion years ago. Pathogenic and environmental species of the order

Chlamydiae are obligate intracellular prokaryotes that split about 700 million years ago.
Environmental species reside within unicellular eukaryotes such as free-living amoeba
and are ubiquitous in nature. Differences between the genome of the recently
characterized Acanthameoba environmental strain UI25 and those of modem pathogenic
species have provided insight into the adaptation of pathogenic family Chlamydiaceae to
their niche in the mammalian cell.
The genome of the UWE25 strain is more than twice the size
those of the pathogenic strains

(~1

(~2.4

million) of

million bp), while a core set of 711 CDS were

conserved among these strains. Adaptation of the pathogenic Chlamydia to mammalian
hosts involved a drastic reduction

(~2000

CDS to 1000 CDS) in genes, many of which

encoded proteins involved in biosynthetic and metabolic pathways. Pathogenic species
are auxotrophic for most amino acids and nucleotides and compete with their host cells
for them. Other adaptations unique to pathogenic Chlamydia include genes encode
possible bacterial adhesins: the major outer membrane protein, MOMP (ompA) and the
polymorphic outer membrane proteins (Pmps). These additions to the pathogenic

5

chlamydial surface likely playa role in attachment to specific host cell types and/or
immune evasion[22].
However, the cysteine-rich outer membrane proteins OmcA and OmcB that make
up Chlamydia's unique disulfide-bonded outer membrane are present in UI25. Unlike
other gram-negative bacteria, Chlamydia do not synthesize a peptidoglycan layer on their
surface for structure, instead highly crosslinked protein complexes of OmcA, OmcB, and
MOMP provide stability and protect EB's from environmental stress[23]. Conserved
genes between UI25 and modem pathogenic Chlamydia indicate the importance of their
gene products for maintaining intracellular survival. In addition to the outer membrane
proteins (OmcAB), these conserved genes encode some inclusion membrane proteins
(Incs), components of the type III secretion system (T3SS), as well as some type III
secretion effectors.

Type III Secretion

Type III Secretion Systems are syringe-like molecular machines that are common
in pathogenic and non-pathogenic gram-negative bacteria and transport specific bacterial
proteins into eukaryotic cells. Pathogenic bacteria often utilize type III secretion systems
deliver effectors that hijack cellular functions such as reorganizing the host cytoskeleton,
modulating immune signaling or apoptotic factors. A more detailed discussion of type III
effector functions will be discussed later. A functional type three secretion system
consists of structural components that make up the inner and outer membrane base, the
needle shaft, tip, and translocator proteins[24]. It also requires cytoplasmic chaperones
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and a membrane bound ATPase to effectively stabilize and deliver effector proteins,
respectively.
These components of Type III Secretion Systems remain conserved across gramnegative species and also share close structural homology with flagellar components.
Such structural conservation has allowed for the quick identification of putative
chlamydial type III secretion proteins in silica analysis based on conserved structural and
genetic domains[25-31]. Many groups have identified putative Chlamydia TTSS
components by these approaches, but because of Chlamydia species' genetic
intractability, it has remained a challenge to confirm the function of these proteins. Most
of our current knowledge of the structure of the chlamydial type III secretion apparatus
comes from the discovery of in vitro protein-protein interactions between chlamydial
type III components.[27, 32-41], while the detection of new chlamydial effectors has
involved expression and secretion of recombinant chlamydial proteins in heterologous
type III secretion systems of other bacteria[3 8, 40-43]. The predicted structure of the
Chlamydia type III secretion apparatus and its components is visualized in Figure 1.
Assembly of the chlamydial type III apparatus begins with sec-dependent
secretion of CdsC, an outer membrane lipoprotein with homology to secretins[44]
followed by secretion of CdsJ into the inner membrane [45], and then CdsD into the
integral membrane to join the former components into a scaffold that spans two bacterial
membranes[31]. CdsD homo logs in other bacteria function as scaffolding proteins to link
CdsC and other integral membrane components. CdsD has been shown to coimmunoprecipitate with other integral membrane proteins as expected[36], but unique
features such as forkhead association domains (FHA) and in vitro phosphorylation are
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puzzling as to the actual role of CdsD in type III secretion[46, 47]. Homology with innermembrane components from Yersinia species indicate that CdsJ provides a scaffold for
the inner membrane components CdsRlS/T/U and V[46]. CdsS and CdsT interact with
the C-ring component CdsQ, while the CdsU homolog in Yersinia Y scU gets cleaved to
allow secretion[48]. CdsD has been shown to interact with the cytoplasmic ATPase
CdsN and with CdsL, a possible negative regulator of ATPase activity[35]. A complex
network of interactions has been shown to occur in vitro between CdsQ, CdsD, CdsN,
and CdsL [35,49]. Upon assembly of the inner membrane and C-ring components, the
machinery becomes secretion competent and secretes its needle subunits CdsF[27],
possibly with the help of the putative molecular ruler protein CdsP[50]. Lastly secretion
of the tip protein, identified as CT584 in C. trachomatis, completes the latent type III
secretion apparatus and is likely to be responsible for activating secretion upon host cell
contact[34]. CopN interacts with the ATPase CdsN and prevents secretion of any
effectors [41, 51]

8

Eukaryotic cell membrane

Outer membrane

Inner Membrane

Figure 1. The Type III Secretion System of Chlamydia.
The chlamydial cds components C- V correspond to their ysc homologues in Yersinia.
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Interaction of the chlamydial EB with the host cell is sensed by the tip protein,
which in tum relays an unknown signal to induce CopN secretion. Unblocked, the type
III apparatus secretes pairs of trans locator proteins (CopB/CopD or CopB2/CopD2) to the
end of the needle such that they can form a pore in the host cell membrane[37, 38, 46].
After secretion of CopN and the translocator proteins, the ATPase is free to interact with
effectors and ensure their translocation into the host cell.
It must be noted however that several of the secreted components and effectors

require or utilize molecular chaperones to be efficiently secreted. Bacterial type III
secretion chaperones have been organized into classes based on the type of substrates
with which they interact. Class I chaperones mediate the translocation of type III
effectors and are typically small (13-16 kDa), have an acidic pI (4-5), and have a
tendency to dimerize. CT043, CT088 (also called Scc1), and CT663 have been predicted
to be Ctrachomatis class I chaperones based on their predicted secondary structure[28,
29,52], but to date their interaction with effector proteins has not been confirmed. A
recent yeast-2-hybrid screen identified an interaction between CT663 and CT088,
indicating formation of a chaperone heterodimer[49]. The same screen also identified a
new class Ib chaperone that was capable of interacting with multiple effectors as well
with the C-ring component CdsQ which was described as the multi-fargo

~ecretion

fhaperone, Mcsc. Characterization of Mcsc by crosslinking also indicated a
homodimeric molecular structure. In addition, CT663 has been shown to interact with
region 4 of the sigma-66 subunit of Chlamydia and the p-subunit of E. coli RNA
polymerase in a fashion typical of anti-sigma factors[53].

10

The translocator proteins are secreted by Class II chaperones which have
tetratricopeptide repeat (TPR) regions. In Chlamydia trachomatis the TPR-containing
chapeorones Scc2 and Scc3 are transcribed in operons with their sets of translocators,
CopB lICopD 1 and CopB2/CopD2, respectively. Scc2 has been demonstrated to interact
with both CopB 1 and CopD 1, but unexpectedly Scc3 has been shown to interact with
CopN, the type III secretion-negative regulator. A third TPR-containing protein, CT274,
has been detected in Chlamydia spp. and its small size and acidic pI indicate that it may
have chaperone function. Novel interactions between CT274 and the hypothetical
proteins CT668 and CT166 indicate possible Chlamydia-specific type III related proteins.
Type III chaperones that are responsible for the stability or secretion or type III
components other than effectors or translocators have been classified as Class III
chaperones[46]. The needle subunit CdsF and molecular ruler protein CdsP have been
demonstrated to interact with chaperone products from their respective operons, cdsEFG
and cdsOP. A yeast-3-hybrid assay indicated that CdsE and CdsG form a heterodimer
that can interact with CdsF[27]. Multiple studies have identified an interaction between
CdsP and its putative chaperone CdsO[33, 54]. Furthermore, CdsO was shown to form
homodimers indicative of type III chaperones. Predicted and experimentally confirmed
type III secretion chaperones and their substrates are summarized in Table 1.
Many roles have been reported for the interaction of Class I type III secretion
chaperones with their cognate substrates. The most popular role for a Class I chaperone
has been to bind approximately the 30-130 N -terminal amino acids of its cognate effector
and to unfold the adjacent N-terminal secretion signal. Some chaperones have also been
demonstrated to increase the solubility of their substrates or prevent their degradation[55-

11

58]. Directly mediating the interaction between the effector and ATPase has also been
reported[59,60]. Less common functions have included blocking secretion-inhibitory
domains or cnzymatic domains of effectors [61, 62].
Many pathogenic bacteria such as Salmonella, E.coli, Shigella, Pseudomonas, and
Yersinia species utilize type III secretion systems to export virulence factors into target
cells[63]. In these bacteria, the type III secretion-related genes are mostly located in
pathogenicity islands or on specific virulence plasmids. However most type III genes in
Chlamydia are spread out among ten operons while a few other type III-related genes are
completely separate in the genome. In fact this disjointed type III structure is conserved
among environmental Chlamydia isolates[64]. Approximately 10% of the Chlamydia
trachomatis serovar D genome is annotated to be type III secretion-related. Considering
the small size of the genome it is likely that these are all functional and necessary for
productive infection.
In addition to type III secretion components, Chlamydia also contains an
incomplete set of flagellar genes. Recent studies have found novel interactions between
chlamydial flagellar and type III components. The flagellar ATPase FliI has been shown
to have ATP-hydrolyzing activity and interacts in vitro with CdsL and CopN.
Furthermore the flagellar homolog (FlhA) to the inner membrane protein CdsV can
interact with CdsU, CdsQ, and CdsL[32]. These findings taken together with the fact that
Chlamydia is non-motile indicate that the interaction of flagellar components with the
type III secretion apparatus may be important in regulating its unique intracellular
lifestyle[32,46].
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Table 1. Chlamydial Type III-Related Chaperones

Interacting partners

Evidence

Ref.

SIc1 (CT043)

TARP (effector)
SIcI (homodimer)

Co-immunoprecipitation and
bacterial 2-hybrid (B2H).
B2H and gel filtration

Thesis

Scc1 (CT088)

Slc2

Yeast and BacteriaI2-hybrid.

[49],
Thesis

Chaperones
Class I (Sl;:cE-like)

Mcsc (CT260)

(heterodimer)

Capl (inc)
CT6I8 (inc)
CT225 (inc)
Mcsc (homodimer)

Yeast 2-hybrid detected
interaction between Mcsc and
CapI, CT618 and CT225)

[49]

Y2H and crosslinking

Slc2 (CT663)

Sigma 66 (RNAP)
Scc1 (chaperone)
Interacts with E.coli RNAP?

Class II (Sl;:cD-like)
Scc2 (CT576,LcrHI)

Scc3 (CT862, LcrH2)

CT274

Y2H

CopB (translocator)
CopD (translocator)
CopN (neg. regulator)

Co-immunoprecipitation
Yeast 2-hybrid

[53]

[49]

[38]

[49]

CT668 (hypothetical)
CTI6I (apparatus?)

Bacterial 2-hybrid

CdsE

CdsF (needle subunit)
CdsG (heterodimer)

Yeast 2-hybrid

[49]

CdsG

CdsF (needle subunit)
CdsE (heterodimer)

Yeast-3-hybrid
Yeast-2-hybrid

[27,49]

Yeast-3-hybrid
Yeast-2-hybrid

[27,49]

[37]

Class III (other)

CdsO (CT670)

CdsP (molecular ruler)
CdsO (homodimer)

Yeast-2-hybrid
Bacterial-2-hybrid and Co-IP
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[33, 65]
[35]

Type III secretion and Chlamydia's developmental cycle
One common feature of all Chlamydia species is their biphasic developmental life
cycle that imposes upon them an obligate intracellular growth restriction. A small noninfectious but metabolically inactive EB, or elementary body, attaches to a eukaryotic cell
membrane by reversible electrostatic-interactions with unknown host receptors. A second
irreversible interaction occurs and entry into the host cell is guaranteed by the
translocation of effectors by a type III secretion apparatus. Pre-formed in the EB and preloaded with virulence factors, the chlamydial type III secretion apparatus translocates its
EB-associated effectors into the host cytosol upon contact.
Because of their complex life cycle, it has been challenging for researchers to
stably introduce nucleic acids into the bacterium. It is not yet possible to make
knockouts, express recombinant proteins or perform small interfering Ribonucleic Acid
(siRNA) knockdowns in Chlamydia. For this reason, much of the characterization of
chlamydial proteins has focused on their interactions in host cells. Thus the roles of
chlamydial type III secreted proteins or effectors in the developmental cycle of

Chlamydia have been a major focus of research.
One particular EB-associated effector, TARP, the Iranslocated Actin Recruitment
rhosphoprotein is detected in the host cytosol minutes after infection and is involved in
hijacking host signaling molecules to the effect of inducing endocytosis of the attached
EB[42,66-73]. Close contact with the eukaryotic cell surface allows interaction of the
EB's disulfide-crosslinked outer membrane with host protein disulfide isomerase (PDI)
such that the chlamydial outer membrane proteins become reduced and its uptake can
occur. Immediately upon uptake into its endocytic vesicle, the EB's DNA starts to
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decondense and it begins to differentiate into a large metabolically active RB or reticulate
body. A small metabolite interrupts the interaction of the chlamydial histone-like
proteins Hc 1 and Hc2 with chromatin and the subsequent decondensation of DNA allows
for transcription of early genes.
Expression of inclusion membrane proteins, IncD-G, by RBs is detected within 2
hours of infection[74-76]. Highly divergent in sequence and function, these proteins
share large bi-Iobal hydrophobic domains of 40-60 amino acids in length that ensure their
localization. Secretion and outer membrane localization of these Incs is pivotal to
forming its unique intracellular niche, the "inclusion," that diverges from the customary
endocytic pathway. IncA, IncG and the Inc CT229 have been demonstrated to be type III
secretion substrates by heterologous bacteria, while the mechanism of secretion of other
Incs is unknown. Characterization ofIncA revealed a eukaryotic SNARE-like domain
that may mediate interaction with host vesicles. Similarly IncA has been shown to
mediate homotypic fusion of inclusion vesicles[75]. Another host mechanism that
Chlamydia mimics to influence the trafficking of host vesicles is the recruitment of Rab

GTPases. The Inc CT229 has been shown to interact with Rab4[77], and the C.
pneumoniae inc Cpn0585 can interact with Rabs 1, 10 and 11 [78]. The Rab6-associating

protein Bicaudal-l has been found localized to the inclusion as well, possibly by the
action of an inc protein[74]. Recruitment of Rab-GTPases to the inclusion can direct
vesicles from the golgi, multivesicular bodies, and recycling pathways to the inclusion
where essential nutrients, amino acids and specialized lipids can be acquired. Another
characteristic of the early inclusion is its recruitment of dynein and subsequent migration
toward the host microtubule organizing center (MTOC)[79].
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A major mechanism of survival of the parasitophorous inclusion is to delay the
host cell cycle and preventing apoptosis. The C.trachomatis IncG proteins have been
shown to sequester the host protein

14-3-3~

and prevent phosphorylation of the pro-

apoptosis protein BAD[80, 81]. Cleavage of the cell cycle regulator cyclin B 1 was also
detected as a consequence of chlamydial infection[82]. The secreted protein CP AF
(Chlamydia protease-like secretion factor) has been shown to have several roles during
infection including degrading BH3-like apoptosis proteins[83].
Other effectors have been shown to be involved in suppressing host inflammatory
signaling. ChlaDubl and CT441 are able to interrupt NFkB-signalling by
deubiquitinating IKBa and by degradation of ReIA, respectively[84, 85]. Sequestering of
Actl by the c.pneumoniae effector CP0236 prevents it interaction with IL-17 and
subsequent NFkB-activation[86]. CPAF has also been implicated in the degradation of
host factors to prevent proper MHC and lipid antigen presentation[75].
As the inclusion becomes modified additional type III secretion needles are
assembled and a second set of effectors is expressed. Expression of mid-cycle genes (616 hours p.i.) allows for intermediate metabolism such that RBs can continue to grow and
multiply by binary fission. Although Chlamydia do not have a peptidoglycan layer, they
are affected by treatment with Penicillin- indicating a possible role for peptidoglycan
during division. This theory is corroborated by the transcription of peptidoglycan
syntheisis genes prior to cell division and the lack of an FtsZ homolog in Chlamydia
species[23]. Possibly by a contact-dependent mechanism, newly divided RBs detach from
the inclusion membrane and differentiate back to small infectious EBs. It has been
proposed that as RBs divide and the inclusion size increases, individual RBs have less
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surface contact with the inclusion membrane and detachment of the RB occurs, possibly
by retraction of type III secretion apparatuses[75, 87, 88]. While microscopic
observations and mathematical models support the contact-dependent model of
detachment, the mechanism connecting detachment and differentiation remains elusive.
Two distinct mechanisms of EB exit have been identified. Ordered
permeabilization of the inclusion membrane, nucleus, and host cell membrane has been
demonstrated to release EB's during cysteine protease-induced cell lysis. Extrusion, or a
slow pinching off of the chlamydial inclusion, has also been observed at nearly the same
frequency as cell lysis during C.trachomatis infection[89]. Future research to define any
differences in infectivity, transmission, and pathogenesis by EB's released by lysis versus
extrusion will be highly anticipated.
Before secondary differentiation, however, proteins important for invasion, such
as bacterial adhesins, components of the type III apparatus and invasion-associated
effectors must be expressed and pre loaded for immediate translocation into the host cell.
Gene expression of type III components have been detected from 8 hours post-infection
onward. However, specific subsets of type III-related genes have been shown to be
temporally regulated[90-93], indicating functions at different points in the developmental
cycle. Evidence of transcription of type III-related genes and their temporal classes are
compiled in Table 2.
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Table 2. Expression of type III genes during the chlamydial developmental cycle.
Temporal class [39,91-93]

Type III function

lncG

E

Effector

CT229 (lnc)

E

Effector

lncA

M

Effector

TARP

M,VL

Effector

Slcl

M

Chaperone (1)

Sccl

C

Chaperone (I)

Slc2

M

Chaperone (I)

FliF (1)

M

Apparatus

FliN (Q)

L

Apparatus

FliA

M

Sigma 28

FlhA (V)

M

Apparatus

Flil (N)

L

ATPase

CdsC

L

Apparatus

CdsE

M

Apparatus

CdsL

M

Apparatus

CdsJ

M

Apparatus

CdsR

M,C

Apparatus

CdsS

M,C

Apparatus

CdsT

L,C

Apparatus

CdsU

M,C

Apparatus

CdsV

M,L

Tip ICap

CT274

M

Chaperone (II)

Scc2

L

Chaperone (Il)

Scc3

M

Chaperone (Il)

CopB

L

Translocator

CopD

L

Translocator

CopB2

M

Translocator

CopD2

M

Translocator

CopN

M

Neg. Regulator

Gene

..
1. E= early, M=MId-cycle, L=Late-cycle, VL= Very Late C=constItUltIvely actIve.
2. Type-III apparatus homolog to Flagellar proteins is in parenthesis.

18

Attachment
The initial association of Chlamydia elementary bodies to the epithelial cell
surface has been shown to involve a heparin-sensitive reversible electrostatic interaction
with host cells. A plethora of data has been accumulated regarding the role of heparansulfate like glycosaminoglycans (GAGs) in this attachment step. Early studies to
determine possible bacterial adhesins demonstrated that infection can be limited by
pretreatment of the bacteria or host cells with heparan-sulfate[94-1 0 1]. Coating of
Chlamydia trachomatis and pneumonaie EBs with heparan-sulfate specific monoclonal
antibody prevents infection[97]. Treatment of host cells or EBs with heparinase or with
chemically-modified heparin-derivatives also prevented infection of C. trachomatis
serovar E and L2 strains [99 , 10 1]. Several groups have attempted to determine the role
of host cell heparan sulfate in attachment by infecting heparan-sulfate deficient mutant
CHO cell lines. A few of these studies have indicated a reduction in attached EBs to
these cell lines, while a more recent study has indicated that host heparan-sulfate is not
necessary for attachment.
Substantial evidence implicates the chlamydial antigen MOMP (major outer
membrane protein) in the initial binding of host cells. It was shown that trypsin-mediated
cleavage of the variable regions of MOMP inhibited C. trachomatis serovar B, but not L2
infection[102,103]. Furthermore, in vitro treatment of host cells with MOMP-specific
antibodies severely abrogates C. trachomatis EB binding and infection. EB-surface
associated MOMP is linked to a glucosamine containing sulphated-polysaccharide that
seems to be important for binding mammalian cells[96, 104-107]. N -glycanase cleavage
of this polysaccharide prevents infection by C. trachomatis strains[1 05, 106, 108]. This
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MOMP-associated GAG has likely complicated the interpretation of the heparin,
heparan-sulfate, and heparinase experiments mentioned earlier.
A second temperature-dependent binding step was discovered by infection of a
mutant CHO cell line with Ctrachomatis L2 strain[109]. Attachment ofEBs to wild-type
CHO cells at 4° C could be reversed by addition of heparin, but attachment at 3rC could
not. Isolation of a mutant cell line that could be competed for binding to EBs by heparin
at 37° C indicated a loss of the second heparin-resistant, temperature-dependent receptor.
Many different host ligands have been proposed as this second receptor that
remains irreversibly bound to EBs. Mannose-6-Phosphate treatment of epithelial cells
can inhibit attachment and entry of C pneumoniae, indicating a possible role for
Mannose-6-Phosphate receptor/Insulin Growth Factor 2 as a receptor[11 0]. Knockdown
of host cell Platelet-derived growth factor receptor-~
treatment with

PDGR~-monoclonal

(PDGFR~)

with siRNA and

antibody reduce EB binding[III].

PDFR~

has also

been indicated as an important player in Chlamydia pneumoniae infection by a recent
systems biology study[ 112]. A recent study of the role of the cellular cystic fibrosis
transmembrane conductance regulator (CFTR) during C trachomatis infection describes
CFTR-dependent uptake of EBs and an increase in EB internalization by CFTRectopically expressing cells[113].
Other bacterial adhesins besides MOMP that have been implicated in host
receptor binding include LPS, the outer membrane complex protein OmcB, and the
polymorphic membrane proteins Pmp6, Pmp20, and Pmp21. OmcB from Ctrachomatis
serovars LGVl and E show GAG-dependent and independent binding to host cells,
respectively, indicating that it may be involved in either the primary or secondary
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attachment step[114]. C. pneumoniae Pmp proteins contain tetrapeptide repeat motifs
that mediate binding to epithelial cells, and a recent study indicates that the presence of
multiple Pmps have an additive effect on attachment to host cells[115].
A complex role for Protein Disulfide Isomerase (PDI) in attachment was also
discovered. Reduced attachment of C. trachomatis to a CHO cell line with a mutatedleader sequence in PDI could be restored by complementation with the full length
PDI[116]. This requirement of PDI for attachment has been confirmed in all other
pathogenic Chlamydia. However, it is suspected that PDI does not behave as an actual
receptor but instead structurally associates with another host receptor to initiate
attachment[117].
While enzymatic activity of host PDI is not necessary for attachment, it is an
absolute requirement for chlamydial entry into epithelial cells. Thus, as the chlamydial
EB is brought in close vicinity of the eukaryotic membrane by electrostatic interactions,
another secondary host receptor in coordination with PDI irreversibly binds and reduces
the crosslinked-outer membrane proteins and initiates uptake events such as the
activation of the type III secretion system. Tight-binding of the type III secretion
apparatus to the host cell membrane could indicate that the type III needle and tip
proteins as possible secondary receptors, though further research in this area is needed to
corroborate or disprove the role of the type III secretion apparatus in attachment.
Despite years of research dedicated to the search for host and chlamydial
receptors that mediate attachment, the use of a variety of host cell types and chlamydial
species has made it difficult to determine a general mechanism for attachment. A
compendium of this work can be found in Tables 3 and 4.
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TABLE 3. CHLAMYDIAL ADHESINS

Adhesin/Receptor

Serovars

Evidence

Ref

MOMP

L2, Cps

I, A 32 kDa EB protein bound Hela cell
exracts and heparin.
2. Infection could be neutralized with mAB
against 31 kDa protein.
3.Trypsin-mediated cleavage ofVD IV
prevented attachment.
4. mAB against VD II and IV blocked
electrostatic interactions.

[118,119]

J, L2

B,L2
B

C. trach
L2

C. trach

Heparin Sulfatelike GAGS

C.trach

L2

LGV,E
Ctr, Cpn

OmcB

LGV,E
Cpneumo.,
L2,E

Ctr,Cpn,Cps

5.Glycan cleaved from 32 kDa protein binds
Hela cells.
6. MOMP carbohydrate mapped to reveal Nlinked high mannose oligosaccharide.
7. Recombinant MOMP competes with EBs
for binding Helas and had reduced binding to
heparin sulfate synthesis-deficient CHO
cells ..
I. Isolation of a heparin-sulfate-like GAG
from EBs recovered from GAG-deficient
CHO cells. Another study was unable to
isolate the chlamydial GAG from EBs
cultured in a separate HS-deficient CHO cell
line.
2. GAG-on intracellular RBs visualized and
cleaved by lyase.
3. Heparin-coated micro spheres were taken
up similarly to EBs.
4. Desulfation of L2 or E EBs by sodium
chorate treatment did not reduce infectivity.
5. Treatment ofCpneumo strains and C.tr E
EBs with heparin derivatives or heparatinase
inhibit infedtion

I. OmcB was identified as binding heparin.
The Binding region was mapped to a 20-mer
peptide whose addition could out-compete
binding by OmcB.
2. Addition of recombinant OmcB from
LGVI but not E prevents EBs from binding
host cells. Attachment of LGV I rOmcB but
not E was abrogated in the presence of
heparin.
3. Expression ofC.pneumo OmcB on Yeast
was sufficient for binding to epithelial cells
and addition of heparin prevented this
binding. Addition of OmcB recombinant
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[119]
[102]
[103, 104]

[105]
[106]
[120]

[121, 122]

[97]
[98]
[123]
[101 ]

[124]

[114]

[125]

protein or monoclonal antibody prevents
C.pneumo EB attachment to host cell.

LPS

Pmps

E,LGV

Cpn, Ll E

I.Chalmydia LPS immunoprecipitates with
CFTR.

1. Recombinant expression of Pmp6, 20, or
21 on yeast cells mediates adhesion to
epithelial cells. Treatment of host cells with
recombinant Pmps or mAb against these
proteins prevents C pneumo infection.
Binding can be attributed to the tetrapeptide
motifs in these proteins.

[113 ]

[115]

TABLE 4. HOST CELL RECEPTORS
Receptor

PDGFRp

CFTR

M6P receptor

Cell types

Evidence

Ref

S2, Hela

I. Treatment of host cells with PDGFR~ siRNA or
mAb reduces C.trachomatis L2 binding.

[111 ]

Hela
CFTR-/- mice

Hela

HMEC-l

PDI

CHO-6

CHO-6, Hela

2. Uptake of C.trachomatis EBs is blocked by
CFTR mAbs and by treatment with CFTR
inhibitors. Also there was a reduction in EB
uptake by CFTR knockout mice. CFTR can also
be co-immunoprecipitated with LPS.

I. Mannose-binding protein interacts with MOMP
and prevents interacation of C.trachomatis with
host cells.
2. Addition ofM6PR or M6P analog prevents
attachment ofC.pneumo but not C.trachomatis
strains to endothelial cells.

1. The CHO-6 cell line is mutant for PDI and is
resistant to attachment that could be recovered
with FL PDI.
2. siRNA knockdown of PDr prevents infection.
Chlamydia does not bind directly to PDI-gpi.

23

[113 ]

[126]

[110]

[116]

[117]

TABLE 4. HOST CELL RECEPTORS (cont.)
Receptor
Heparinsulfate

Cell types

Evidence

Ref

Hela

I. 32 kDa and IS kDa EB surface proteins are
prevented from binding host cell by heparin.
2. Infection inhibited by adding heparin-sulfate
receptor or heparatinase.
3. Heparatinase treatment of LGV and trachoma
EBs prevented attachment.
4. Heparin inhibition of LGV and trachoma biovar
infections was rescued by competition with a
sulphated decasaccharide.
5. A heparin sulfate synthesis-deficient CHO cell
line had reduced EB infectivity. A separate HSdeficient CHO cell line was resisitant LGV but not
E infection.
6. Attachment of LGV EBs to was completely
inhibited by pretreatment with heparin or
heparatinase.
7. Attachment of Trachoma biovar EBs was only
partially inhibted by heparin or heparatinase
pretreatment.
S. Serovar E attachment not inhibited
by heparin or heparan sulfate, but L2 was
completely inhibited.
9. Heparatinase blocked C.psittaci EB attachment
at 4° and 37° while heparin blocked attachment at
4°.
10. Inhibition ofC.trachomatis infectivity by
sulphated polymers or polysaccharides in vitro (eel
culture) but not in vivo (mouse model)
II. Heparin sulfate mAb binds to C. trach and C.pn
EB surface and neutralizes infectivity.
12. Heparatinase treatment of host cells prevented
L2 infection and the HS-synthesis deficient CHO
cell line was less sensitive to infection.
13. Desulfation of host cells by sodium chlorate
inhibited L2 but not E infection.
14. The HS mutant cell line CHO-IS.4 was
infected equally by L2 and D and was comparable
to infection ofWT CHO cells.
I5.Treatment of host cells with heparinase and
heparin derivatives prevented infection by C.pn
strains and C.tr E.
16. OmcB-expressing yeast from Cpn and C.tr-L I
were unable to bind heparatinase treated or GAGdeficient CHO cells.

[118]

Hela, CH0761
L929, Hela
Hela, L929

CHO

L929,Hela
CHO

Hela, McCoy
Hela, McCoy

Hela
Hela?
Hela, CHO
McCoy, Hela
CHO
HL

CHO
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[121, 127]
[127]
[94]

[120]

[107,122]
[107,128]

[128]
[95]

[96]

[97]
[99]
[123]
[100]
[101 ]
[125]

Entry

Following attachment of EBs, uptake by the endocytic pathway is induced by
chlamydial factors. Uptake of chlamydial EBs by epithelial cells is associated with the
recruitment of actin and tyrosine phosphorylation of proteins at the site of entry for

Ctrachomatis[42, 73, 129, 130]. This actin recruitment is dependent on the activation of
the small Rho GTPase Rac in Ctrachomatis infection, while both Cdc42 and Rac
activation are important for C caviae entry[72, 131]. A tyrosine-phosphorylated protein
associated with actin recruitment has been identified to be the chlamydial type III
translocated protein TARP. Ctrachomatis LGV TARP contains six tyrosine-rich repeat
domains that can be tyrosine phosphorylated by several host kinases containing the Srchomology 2 -domain (SH2). The SH2-containing kinases Src, Yes, Fyn, Syk, and Abl
are all able to phosphorylate tyrosine residues ofC.trachomatis TARP[66, 68,132]. The
observation that individual knockdown of anyone of these kinases does not completely
abrogate tyrosine phosphorylation reinforces the importance of TARP phosphorylation
for efficient manipulation of host signaling cascades and actin remodeling. Type III
effector-induced actin polymerization and cytoskeletal rearrangement has been
extensively studied in other bacteria pathogens. Enteropathogenic E. coli stimulates acitnpedestal formation through the type III translocation ofTir (translocated intimin receptor)
into host cells where it is tyrosine-phosphorylated and associated with Arp2/3
recruitment[133, 134]. The SPI-l (Salmonella Pathogenicity Island-I) type III secretion
system induces bacterial uptake by translocation of effectors that induce membrane
ruffling and Rho GTPase activation[135].
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Tyrosine phosphorylated residues in C trachomatis TARP are able to recruit the
guanine nucleotide exchange factors Sos-I and Vav-2[67, 68]. A complex ofSos-I,
Eps8, and Abi-I or Vav-2 with PIP3 (phospho-inositoI3,4,5-P 3 ) have been shown to
activate Rae in a phosphotyrosine dependent manner[67]. Rae-dependent recruitment of
actin has been shown to involve Abi-I and WAVE-2 dependent formation of the actinnucleating Arp 2/3 complex[69]. While Ctrachomatis L2 and D TARPs contain 6 and 3
tyrosine-rich repeats (TRR), respectively, Ccaviae, Cpneumoniae, and Cpsittaci do not
contain TRRs. All chlamydial TARPs do contain proline-rich domains that induce TARP
aggregation and C-terminal WH2-like domains that are capable of nucleating actin [70].
It has been proposed that the WH2 domains on TARP may contribute to the further

polymerization of the short actin filaments already induced by the Arp2/3 complex[69].
A recent protein microarray indicated the interaction of an SH2-containing
adaptor protein SHC 1 with TARP derived phosphopeptides. Infection of SHC 1
knockdown cells sensitized Chlamydia to TNF-induced apoptosis, and detection of
SHC I-regulated genes included those involved in apoptosis and growth[136]. Taken
together, previous findings clearly indicate that TARP plays a critical role in the entry
and survival of Chlamydia trachomatis in host cells, and thus its translocation through the
bacterial type III secretion apparatus into mammalian cells must be absolutely efficient to
ensure survival of the organism.
Besides TARP, the EB-associated type III effectors CTI66 and CT694 have been
reported to be associated with entry-related signaling. As a homolog to the chlostridial
glucosylating toxins, the mono-glucosylation and subsequent deactivation of Rac by
CTI66 has been demonstrated in Hela cells. Since this effector is translocated into host
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cells shortly after infection it is likely that it provides a balance to the actin remodeling
induced by TARP during C. trachomatis entry[ 13 7]. The association of CT694 with the
host protein AHNAK to alter stress fibers may also be important for invasion.[138]
Tyrosine-phosphorylation of the host protein Ezrin has also been discovered as a
direct result of C. trachomatis infection of epithelial cells[ 13 9]. Like TARP, the tyrosinephosphorylation of Ezrin upon infection led to its association with actin, specifically in
microvilli.[140] The specific kinase(s) involved in Ezrin tyrosine phosphorylation during

Chlamydia infection have not been determined, but previous studies have demonstrated
that this event can be a direct result of host receptor binding and activation[141].
Chlamydial attachment to and subsequent phosphorylation of PDGFR~ results in
phosphorylation of W A VE2, Cortactin, and the guanine-exchange factor Vav2 [111].
Phosphorylation and subsequent activation of these molecules is associated with actinremodeling events. It is clear that multiple and redundant signaling pathways are
hijacked by Chlamydia species to ensure efficient uptake of the organism. Upon cell
contact, immediate secretion of chlamydial factors such as T ARP into the host cytosol is
critical for initiating actin-cytoskeletal remodeling and subsequent endocytosis of the EB.
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HYPOTHESIS

I hypothesize that a chlamydial factor is responsible for the efficient association
of TARP with the type III secretion apparatus and its ensuing translocation into the host
cell cytosol. I propose that the Chlamydia trachomatis Class I type III secretion
chaperone SIc 1 interacts with T ARP and is responsible for its efficient translocation
through the type III apparatus.
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CHAPTER II.

MATERIALS AND METHODS

Bacterial strains and cell culture.
Chemically competent Top10 and BL21star E. coli strains from Invitrogen were used for
plasmid propagation and protein expression, respectively. The adenylate cyclase (cya)
deficient DHM1 E. coli strains were grown at 30° C on indicator plates (LB + 40 flg/ml
X-gal + 1mM IPTG or McConkey + 1% maltose) for 48 hours or in Luria-Bertani broth
(LB) at 37°C. All other E. coli strains were grown at 37° C in LB broth or agar plates.
The Yersinia enterocolitica WT strain MRS40 or L1 Y scN E40(PMSI41) strain were
grown in LB or Brain-Heart-Infusion (BHI) broth at 26° C. Media was supplemented
with 100 flg/ml carbenicillin (carb), 60 flg/ml kanamycin (kan), 12.5 flg/ml tetracycline
(tet), or 35 flg/ml Nalidixic Acid, when appropriate. The wild-type EPEC serotype
0127:H6 strain E234/69 and the cesT knockout strain were obtained from Gadi Frankel's
lab and grown in LB broth. The Salmonella eneterica typhimurium strain 12023s was
obtained from David Holden's lab and grown in LB broth. Hela cells were cultivated at
37° C with 5% CO 2 in DMEM supplementedwith10% FBS and 2 mM L-glutamine.

Plasmid construction.
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Slc l, Scc1, Mcsc, Slc2, and the N -terminal 600 nucleotides of TARP were amplified
from Chlamydia trachomatis genomic DNA (gDNA), CesT and the N-terminal 600 nt of
Tir from enteropathogenic E. coli gDNA, and YopH from Yenterocolitica MRS40
gDNA by the polymerase chain reaction (PCR) using the primers listed in Table 5.
Cloning into pETlOl, pET200, pBAD-TOPO and pENTR-D/SD-TOPO utilized the
endogenous topoisomerase activity of Invitrogen directional cloning vectors. The PCR
fragments CACC-CT043-FLAG-stop (and CACC-CT663-FLAG-stop were cloned into
pETlOlID-TOPO, resulting in the plasmids pETlOl-Slc1-FLAG and pETlOl-Slc2FLAG, respectively. The PCR fragment CACC-TARp l -200 was cloned into pET200/DTOPO, resulting in the plasmid pET200-TARp l -200 . All of the constructed plasmids were
transformed into TopiO cells, recovered in SOC medium for one hour at 37° C, and
plated on LB agar supplemented with carb, kan or both. The resulting colonies were
restreaked and grown overnight. Presence of the correct plasmid inserts was confirmed
by colony PCR and sequencing. The PCR fragments CACC-CT043 and CACC-CT088FLAG were cloned into pENTRISD/D-TOPO, resulting in the plasmids pENTR-Slci and
pENTR-Scci-FLAG, respectively. These new entry vectors were recombined with pET56-DEST using LR recombinase II reaction mix (Invitrogen), transformed into Top 10,
and selected for on LB+carb agar overnight. The resulting colonies were restreaked on
carb plates and grown overnight. The presence of the correct plasmids was determined
by colony PCR and sequencing. Plasmid DNA was purified from the TopiO genetically
modified strains by using Qiaprep Spin Miniprep Kit.(Qiagen). The BL2I star expression
strain was singly or co-transformed with pET200-TARP200, pETlOI-SlcI, pETlOI-Slc2,
and pET56-Scc I-FLAG. For the expression of chlamydial proteins in Yersinia, I digested
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Slc2 and Scc1 from petl0l-Slc2 and petlO1-Scc1 with XbaI and ScaI-HF (NEB). These
digested inserts were then ligated into the XbaI and Seal sites of pBAD 18 (American
Tissue Culture Collection). Mcsc and SIc1 were cloned into the pBAD-TOPO vector.
SLIM PCR was used to add a KpnI sited downstream of TARP in the vector pet200TARp l -200 to form pet200_TARp l -200 -kpnI. This vector was then digested with NdeI and
KpnI and the resulting NdeI-TARp l -200 -KpnI fragment was cloned into these sites in
pCX340. For co-expression in the bacterial2-hybrid system, all of the PCR inserts were
generated to have flanking XbaI and KpnI sites and were cloned into the same sites in
pUT18C and/or pKT25 prior to co-electroporation into DHMI E. coli.

Protein expression, lysate preparation, and protein purification.

Overnight cultures of BL21 star strains were diluted 1:20 in LB + antibiotic, and grown
to OD 600 of 0.6. Expression of recombinant proteins was induced by addition of 0.5 mM
isopropyl-P-D thiogalactopyranoside (lPTG) and incubated for 3 hours with shaking.
Bacteria were centrifuged at 8000g for 20 minutes, and the pellet was resuspended in
III 0 culture volume of lysis buffer (50mM NaH 2 P0 4 , 300mM NaCI, 0.05% TIen, 0.1
mg/ml Dnase I, 1 mg/mllysozyme, Halt Protease Inhibitor Cocktail (Pierce)). For
preparation of lysates that were added to NiNta Magnetic Beads, 25 mM imidazole was
added to the lysis buffer. Bacteria were incubated in lysis buffer for 30 minutes at room
temperature, sonicated to shear DNA, and stored at -80°C. Purifications of Slcl-FLAG
and His6- TARp l -200 for use in crosslinking and gel filtration experiments were
performed using M2-Anti-FLAG agarose (Sigma) and Ni-Nta Agarose (Qiagen),
respecitively. Lysozyme was left out of the lysis buffer and the french press was used to
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release soluble proteins from these lysates prior to clearing by centrifugation at 15,000 g
for 30 minutes. Purification fractions were run on 12% SDS-PAGE gels and proteins
were stained with a 0.2% Coomassie Blue R250 solution.

Coimmunoprecipitation assays and immunodetection.
Bacterial expression lysates were thawed and partially cleared by centrifugation at 4000g
for 15 minutes prior to addition to M2 Anti-FLAG Agarose (Sigma) or NiNta Magnetic
Beads (Qiagen). 30 mM imidazole was added to 500 ).1llysates prior to incubation with
the magnetic beads on an end-over-end rotator overnight at 4°C. The flow-through
fraction or supernatant was separated from the beads with a magnetic separator, and the
beads were washed five times with NiNta Native Wash Buffer (50 mM Na2HP04, 300
mM NaCl, 20 mM imidazole, 0.05% TIen 20, PH 8.0). The first (WI) and fifth (FW)
wash fractions were kept for analysis, and the native protein complexes were eluted from
the beads by incubation with 100 ).11 NiNta Native Elution Buffer (50 mM Na2HP04, 300
mM NaCl, 300 mM imidazole, 0.05% Tlen 20, pH 8.0) at 4°C for 4 hours. For each
coimmunoprecipitation experiment with M2 Anti-FLAG agarose, 1 mlofbacteriallysate
was added to 100 ).11 of packed agarose resin and incubated on an end -over-end rotator at
4°C overnight. The flow-through fractions were collected by centrifugation at 3000 g for
1 minute, and the resin was washed five times with tris-buffered saline (TBS, prior to
elution of the native protein complexes by incubation with 100 ).11 of 200 ng/ml 3XFLAG
peptide (Sigma) in TBS at 4°C for 4 hours-overnight. Immunoprecipitations of S-tagged
proteins were done as per the S-tag ReK purification kit manual. (Novagen).
Immunoprecipitation fractions were incubated 1: 1 with Laemmli sample buffer (Biorad)
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+ 0.5 %

~-mercaptoethanol

at 95°C for 10 minutes prior to separation by SDS-PAGE.

Proteins were transferred to polyvinylidine fluoride (PVDF) membrane and detected by
Western blot probed with 6XHIS, DDDDK, and S-tag specific antibodies from Abcam
(cat#: ab18588, ab21536, ab18184, ab49763, abI187). HRP-conjugated goat-anti-mouse
(Millipore 12-349) or HRP-goat-anti-rabbit (Pierce #185415) were used as secondary
antibodies when necessary, followed by development with Millipore Immobilin Western
Substrate.

~-galactosidase

assay.

A modified Miller assay was followed[142]. Briefly, co-expressing DHMI strains were
grown overnight in LB+antibiotic at 37°C followed by a 1:50 subculture and growth in
fresh LB+antibiotic to an OD600 of 0.5-0.8. The OD600 of the culture was recoded and
20 ul of culture was added to 80 ul of permeabilization buffer (20 mM KCl, 2 mM
MgS0 4, 0.8 mg/mL CTAB (hexadecyltrimethylammonium bromide), 0.4 mg/mL sodium
deoxycholate, 5.4 llL/mL beta-mercaptoethanol) and incubated at 30° C for 30 minutes.
The time was recorded as 600 ul of pre-warmed substrate solution (60 mM Na2HP04, 40
mM NaH2P04, 1 mg/mL

o-nitrophenyl-~-D-Galactoside

(ONPG), 2.7 llL/mL

~

mercaptoethanol) was added to each permeabilized sample and incubated at 30°C. Upon
developing a yellow color, the samples were stopped with 700 ul of 1 M Sodium
Carbonate (Na2C03) and the stop time was noted.

Co localization assay.
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The open reading frames of SIc 1 and Slc2 were cloned into pENTR/D- TOPO and
recombined into pDest-N-mcherry by the LR recombinase reaction as described by the
Gateway expression manual. (Invitrogen) Mcherry-Slc1, Mcherry-Slc2, or Mcherry gus
were co-transfected with full length C. caviae GFP-TARP into Cos-7 cells with Fugene 6
Transfection Reagent as indicated in the Fugene 6 Technical Bulletin. (Roche)
Transfected constructs were expressed for 24 hrs before the cells were fixed with 4%
Paraformaldehyde on glass coverslips and analyzed with an Olympus Fluoview 500
Laser Scanning Microscope.

Secretion Assay.

Overnight cultures of Y.enterocolitica strains containing pcx340 and pBAD vectors were
diluted to an OD600 of 0.2 in 5 ml ofBHI + 2.5 mM CaCl2 (represses Yop production)
or BHI + 0.4% glucose + 5 mM EGTA + 20 mM MgCl2 (induces Yop production) for 2
hours at 26° C. Expression of recombinant proteins were induced with the addition of 1
mM IPTG and 13 mM L-Arabinose, upon shifting to 37°C (type III secretion-inducing
conditions). Secretion was induced for 4 hours prior to centrifugation at 3000g for 20
min. The top 9 ml of the supernatant were removed and respun at 12000g for 30 minutes
at 4°C. This supernatant was further cleared with a 0.45 uM filter and proteins were
precipitated with ice-cold 10% TCA. Precipitated proteins were pelleted, washed twice
with ice-cold acetone, and dried prior to resuspension in a proportional volume of Lysis
buffer B (0.1 M Tris-Hcl, 0.1 M NaH2P04, 300 mM NaCI, 6 M Urea) to cell pellet.
Lysates were treated 1: 1 with Laemmli + 5%

~ME

and heated to 95° C for 15 minutes

priort to separation on a 12% SDS-PAGE gel. Protein concentration in the whole-cell
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pellet was determined by bicinchoninic acid assay (BCA) and the protein in whole-cell
pellets was normalized to 1 mg/ml in Lysis buffer B.

Yersinia enterocolitica Translocation Assay.
Hela cells were plated in black, flat, glass-bottomed 96-Ill plates at a density of 1 X 104
cells per III and allold to grow for 24 hours prior to infection. One day prior to infection
TEM-1 fusion protein (pcx340) and pBAD18-chaperone expressing Y enterocolitica
strains were inoculated into 3 ml of BHI broth + tet ± carb and grown at 26° C overnight.
The following day, the cultures were diluted 1:20 in BHI + antibiotics and grown at 26 C
for 1 hr. 1 mM IPTG and 13 mM L-Arabinose were added to the cultures and were
grown for 2 more hours at 26° C. Monolayers were washed twice with HBSS, and
infected with Yenterocolitica at an MOl of 10. After 1 hr of infection at 37°C, the
monolayer was washed twice and fresh DMEM was added. The infection progressed for
2 more hours at 37° C in 5% CO 2 . Infected cells were washed 3 times with HBSS and
topped with lOOul ofHBSS. The 1xCCF2/AM substrate was prepared as per the
manufacturer's manual (Invitrogen) and 20 ul was added to each Ill. Infected cells were
incubated at RT for 1.5 hrs in the dark prior to fluorescence detection at 450 and 520 nm
with a fluorimeter (excitation at 410 nm).

Enterropathogenic E.coli and Salmonella typhiumurium translocation assays.

Enterropathogenic E.coli or Salmonella typhimurium was inoculated into LB broth +
tetracycline and chloramphenicol and allowed to grow at 37° C overnight. Cultures were
diluted 1:33 in fresh LB broth + antibiotics and allowed to grow to mid-log phase at 37°
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C (shaking for Salmonella, no shaking for EPEC). Bacteria were pelleted, washed and
resuspended in PBS and added to 80% confluent HeLa cell mono layers at a multiplicity
of infection (MOl) of 50. For the EPEC and SPl-1 assays, the mono layers were infected
for 2 hours prior to the washing and CCF2/AM steps (see above), while the Salmonella
were allowed to infect cells for 9 hours in the SPI-2 assay at an MOl of 10.
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CHAPTER III
IDENTIFYING INTERACTIONS BETWEEN TARP AND TYPE III
CHAPERONES FROM CHLAMYDIA TRACHOMA TIS

Since TARP translocation is a critical event that ensures the uptake and survival
of Chlamydia, I sought to identify any type III secretion chaperones that may facilitate its
translocation. From earlier in silica studies, I knew that three such type III class I
(effector) chaperones were predicted in C. trachomatis genome. I manually aligned the
predicted secondary structures of the open reading frames CT043, CT088, and CT663
with known class I effector chaperones from other pathogenic bacteria (Figure 2). In this
figure I annotated the aforementioned chaperones as SIc1, Scc1, and Slc2. Previous
studies had coined Scc 1 (Specific Chlamydial Chaperone 1) for CT088 [41]. Throughout
this study I refer to CT043 and CT663 as SIcI and SIc2 for furcE-L.ike Chaperone 1 and
2, respectively.
The predicted chlamydial chaperones shared the

a-~-~-~-a-~-~

secondary

structure characteristic of type III effector chaperones. Interestingly, all three putative
chaperones were reported to be present in the elementary body proteome, [143-146]
suggesting that these chaperones may function in the translocation of EB-associated
effectors. These findings convinced us to test these putative chlamydial chaperones for
their ability to interact with the invasion-associated effector TARP.
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Figure 2. Secondary structure alignment of type III chaperones.
Three C trachomatis proteins share predicted secondary structural features characteristic
of known type III export chaperones. Primary amino acid sequence alignment of known
type III export chaperones CesT (EPEC), SycE (Yersinia enterocolitica) and SicP
(Salmonella enterica serovar typhimurium) with the putative export chaperones Slcl
(CT043), Slc2 (CT663) and Scc1 (CT088) of Ctrachomatis. Secondary structure was
predicted using Jpred and sequences aligned manually to according to the a -~-~-~-a - ~ 
~-a signature characteristic of some type III export chaperones. Residues predicted to
form a-helices and ~-strands are highlighted dark grey and light grey, respectively.
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Interaction of the N-terminal200 amino acids ofTARP with the chaperone SIc1.
Since chaperones typically bind their effectors within the N-terminal 30-150
amino acids, I chose to test the N -terminal 200 amino acids of TARP for binding by the
three putative chlamydial chaperones Slc 1, Slc2, and Sccl. I utilized two independent
approaches - co-immunoprecipitation and the bacterial two-hybrid system to confirm a
chaperone-binding partner for TARP. Both of these approaches alloId us to identify
interactions between native recombinant proteins and have both been used previously to
identify type III chaperone:effector interactions[38, 147]. Co-immunoprecipitation is a
directed blunt-force approach for identifying in vitro interactions, while the bacterial twohybrid assay allows for real-time interaction of expressed proteins and is conducive to
quantitative analysis.
For bacterial expression in the co-immunoprecipitation assays, I cloned the Nterminal 200 amino acids of L2 TARP into pET200 (Figure 3) and expressed the
recombinant N-terminus ofTARP with an N-terminal6XHIS tag (HIS6_TARpl-200).
Each of the predicted chlamydial chaperones were cloned into pETl 01 (Figure 5) and
expressed to have C-terminal FLAG tags. A stop codon was included after the FLAG tag
to exclude the vector-encoded 6XHIS tag from the chaperone open reading frame.
Expression of recombinant TARP and chaperones such that they had different tags allold
us to purify interacting proteins using two different immobilization approaches: HIS 6TARp l-200 with Ni-Nta magnetic beads or chaperone-FLAG with M2 Anti-FLAG
agarose. The separate recombinant tags for TARP and chaperones were also important
for immunodetection by Western blot analysis.
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The open reading frames of the N-terminal200 amino acids ofTARP were
amplified from Ctrachomatis Serovar L2, Mouse pneumonitis, Cpneumoniae, and
C caviae by PCR. (Fig 3) SIc I, Sccl, and Slc2 were amplified from C trachomatis

serovar L2 genomic DNA by PCR. (Fig 5) The purified PCR products were cloned into
Invitrogen's directional cloning vectors (pET200 and pETIOI) by using the energy stored
in a bond between the 3' phosphate of the linear vector and Vaccinia virus topoisomerase
I to join the 5' CACC overhang from PCR products with the GTGG overhang of the
. linear vector. This allows for directional blunt-end annealing of the PCR products to the
linear vectors without any digestion and ligation steps. Transformation of these cloned
vectors into chemically competent Top IO cells gave a high yield on antibiotic-selective
plates, and colonies were checked for correct inserts by colony PCR. (Figures 4 and 6)
Plasmid DNA from each positive clone was confirmed for the correct inserts by
sequencing (Genomic Core-Baxter II, University of Louisville).
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Figure 3. Amplification of T ARP inserts for cloning into pET200.
(Top) Vector diagram of the pET200 directional topo cloning vector from Invitrogen.
(Bottom) PCR-amplified inserts of the N-terminal200 amino acids ofTARP from
different Chlamydial species are displayed on a 1% agarose gel.
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Fig 4. Colony PCR of transformants of pET200- TARP 1-200.
Colony PCR was performed on kanamycin-selected transformants and the 1.2% agarose
gels displayed here indicate the foresence of the TARP200aa inserts for each Chlamydia I
species in the pET200-TARp l -2 0 vector.
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Figure S. Amplification of chaperone inserts for cloning into pETIOl.
(Top) Vector diagram of the pETlOl rectional topo cloning vector from Invitrogen.
(Bottom) PeR-amplified inserts of the putative type III secretion chaperones from C.
trachomatis serovar L2 are displayed on a 1% agarose gel.
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Fig 6. Colony PCR of transformants of pETIOl-chaperones.
Colony PCR was performed on kanamycin-selected transformants and the 1.2% agarose
gels displayed here indicate the presence of Ctrachomatis serovar L2 CT663 , CT088,
and CT043 inse11s in the pETI0l vector.
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Cleared BL21 star E.coli lysates containing HIS6-TARpl-200, chaperone-FLAG, or
a mixture of the 2 lysates were incubated with M2 Anti-FLAG agarose for 4 hours at 4°C
to allow protein complexes to form and become immobilized on the agarose. After 5
wash steps to remove any non-specific proteins, I eluted the protein complexes with 250
mM 125 Ilg/mI3XFLAG peptide. The specific retention ofTARP by the chaperones was
monitored in the flow-through, wash, and elution fractions by Western blot analysis

(Figure 7).
The M2 Anti-FLAG beads retained HIS6-TARpl-200 in the presence of
recombinant SIc1, but not Slc2 or Scc1 indicating a specific interaction with SIc 1, but not
the other chaperones. HIS 6-TARP 1-200 was present in all of the co-immunoprecipitation
samples as evidenced by its presence in the flow-through fraction, therefore the lack of
interaction with SIc2 and Scc 1 was not due to an absence of TARP in the combined
lysates. I can also eliminate excess protein forcing an interaction because the low level of
Imidazole (20 mM) in the wash buffer in combination with the multiple wash steps
should eliminate any non-specific interactions. One minor caveat of this approach is that
mixing of separately expressed, prefolded proteins may not be ideal for studying their
native interaction.

45

Chaperone-FLAG
FT

W1

FW

His-Tarp 1.200

E

His-Tarp 1.200
Slc1
Slc1 + His-Tarp1.200

L."

"

SIc2
SIc2 +His-Tarp1.200

Scc1
Scc1 +His-Tarp1.200

I!!!ii!t===~

Figure 7. Pull-down of TARP by chlamydial chaperones from singly expressed
Iysates. Irnmunoblots of flow-through (FT), first wash (WI), final wash (FW), and
elution (E) fractions following M2 Anti-FLAG co-immunoprecipitation ofSlci-FLAG,
Slc2-FLAG or Scc1-FLAG in the presence or absence of His 6-TARP'-200from laboratory
Ecoli lysates following individual expression were detected using anti-FLAG and antiHis 6 antibodies, respectively.
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To confirm the observed SIcl binding to HIS6_TARPI-200, I performed the reverse
co-immunoprecipitation reaction in which TARP was immobilized to Ni-Nta magnetic
beads and monitored the different fractions for SIcI-FLAG content by Western blot
(Figure 8). In this experiment, lysate from a BL21 star E. coli strain that co-expresses

SIc1-FLAG and HIS6_TARpl-200 was incubated with Ni-Nta magnetic beads. Fractions
were processed and detected as stated previously. As expected, I found that the Ni-Nta
magnetic beads when co-expressed with HIS6-TARPI-200 retained high levels of
recombinant SIc 1, but none was retained in its absence.
In addition, I tested whether co-expression of Scc1 or Slc2 with TARP enhanced

their interaction (data not shown) and I was unable to detect any Scc1 or SIc2 in the
elution fraction, giving confirmation that TARP interacts specifically with the putative
chaperone SIc 1. I also observed a relatively higher level of TARP retained in the reverse
co-immunoprecipitation experiment that utilized lysates from E. coli co-expressing both
TARP and Sicl.
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Figure 8. Pulldown of chaperones by T ARP following coexpression
Immunoblots of flow-through (FT), final wash (FW), and elution (E) fractions following
Ni-Nta immunoprecipitation of His6_TARPI-200 from laboratory Ecoli lysates following
expression ofTARpl-200-His6 or SIc1-FLAG alone, or after co-expression as indicated_
SIc1-FLAG and TARPI-200_His6 were detected using anti-FLAG and anti-His 6,
respectively_
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To confirm independently the Slcl-TARP interaction demonstrated by coimmunoprecipitation, the bacterial two-hybrid technique was used[148, 149]. The Nterminus of chlamydial TARP was fused to the C-terminus of the Bordatella pertussis
adenylate cyclase (cya) 18-fragment (CyaJ8-TARP) in the vector pUT18C (Fig 9). Each
of the chlamydial chaperones, including the recently described Mcsc, which has a
chaperone-like activity, was cloned into the vector pKT25 (Figure 9) and expressed as Cterminal fusions to the 25 fragment of cya (Cya25-SIc1, Cya25-Scc1, Cya25-Mcsc, and
Cya25-Slc2). The TARP and chaperone inserts were amplified by PCR and ligated into
the XbaI and Kpnl sites of the pUT18C and pKT25 (Figures 10 and 11) vectors,
respectively. The ligated vectors were transformed into BL21 star and transformants were
checked for the correct inserts by colony PCR followed by DNA sequencing (Fig 10 and
11).
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Figure 9. Diagram of the pUT18C and pKT25 ~-Iactamase fusion vectors.
(Top) Diagram of the pUT18C vector. (Bottom) Diagram of the pKT25 vector.
Colony PCRs of ampicillin-selected pUT 18C-T ARPOO transform ants separated on a 1 %
Agarose gel.
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Figure 10. Cloning of the N-terminus ofTARP into pUT18C.
(Top) PCR of the TARP200aa insert with XbaI and KpnI sites run out on a 1.2%
Agarose gel. (Bottom) Colony PCR of the ampicillin-selected pUT18C-T ARP200aa
transformants run out on a 1.2 % Agarose gel.
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Figure 11. Confirmation of pKT25-chaperone transformants.
Kanamycin-selected pKT25 transformants were checked for their chlamydial chaperone
inserts. Colony PCR for SIcI (Top left), Mcsc (Top right), Scc1 (Bottom left) and CT663
(Bottom right) were separated on 1.2% agarose gels.
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Figure 12. Diagram of the E.coli 2-hybrid system.
Co-expression of the TI8 and T25 fusion proteins in adenylate cyclase-deficient (cya)
E.coli yields two scenarios: 1. (Left) The fusion proteins do not interact and the cya toxin
is not reconstituted. No cylic-AMP (cAMP) is formed and the lactose and maltose
operons are not transcribed. 2. (Right) The fusion proteins interact, bringing together the
T18 and T25 fragments and reconstituting the toxin. Cya mediates the formation of
cAMP, and it fmiher interacts with the catabolite activator protein (CAP) to co-activate
transcription of lactose and maltose operons.
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These fusion vectors were then co-expressed in the cya deficient E. coli strain
DHM1. In this bacterial2-hybrid assay, interaction between fusion proteins results in the
reconstitution of the adenyl ate cylcase (cya) enzymatic domain and catalyzes the
conversion of ATP to (cAMP). Available cAMP, along with the catabolite activator
protein (CAP) co-activates the maltose and lactose operons (Fig 12). Activation of the
lactose operon leads to Beta-galactosidase (p-gal) production, which cleaves the
colorimetric substrate X-gal to yield blue colonies on LB + x-gal + IPTG plates. IPTG
was included in the plates to relieve repression of the endogenous lactose operon by lac!.
Activation of the maltose operon in colonies growing on McConkey + 1% maltose plates
leads to a color change of the phenol red in the agar to fuchsia in the presence of acidic
maltose degradation products[148, 149]. This bacterial2-hybrid system gives quick,
reproducible results on indicator plates, and protein-protein interactions can be quantified
in a

~-galactosidase

reporter assay. I was able to detect an interaction between Cyal8-

TARP and Cya2s-SIc1 by blue and fuchsia colonies on X-gal and McConkey plates,
respectively (Figure 13). Bacteria co-expressing Cya 18-TARP and Cya25-Scc 1, Cya2SMcsc, or Cya25-Slc2 were similar to the negative control, and did not produce an obvious
color change to blue or fuchsia on indicator media.
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Figure 13. Bacterial2-hybrid interactions between TARP and chaperones on
indicator plates.
LB + X-gal + IPTG (left) or McConkey + maltose (right) agarose plates indicate
interaction between co-expressed Cya15 or Cya18 fused chlamydial chaperones in the
cya deficient E. coli strain DHM 1. Upregulation of the lactose and maltose operons
results from fusion-protein interaction and is indicated by blue or fuchsia bacteria. These
results are representative of multiple trials.
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The results obtained from colonies on indicator plates were confirmed and
quantified by monitoring p-galactosidase activity as previously described. Briefly, I
permeabilized co-expressing DHMI strains and measured the p-gal-mediated conversion
of ONPG to the colorimetric molecule ONP. This measurement of p-gal activity was
converted to Miller Units in order to take into account the cell number and length of time
for color development in contrast to the indicator plate method that does not take
bacterial cell numbers into account. The background level of interaction in the Cyal8Empty/ Cya2s-Empty co-expressing strain was subtracted from the Miller Units for each
sample.
Extracts from DHMI strains co-expressing SIcI and TARP indicated 3-fold
higher level of p-galactosidase production compared to the strain containing Slc2 and
TARP (Figure 14). Both the Slc2/TARP and Sccl/TARP co-expressing DHMI extracts
contained roughly 5-fold less p-galactosidase than the Slcl/TARP coexpressing strain.
These results confirm the findings for a TARP-SIcl interaction shown on indicator plates
and in the co-immunoprecipitation assay.
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Figure 14. f3-galactosidase activity of TARP:chaperone bacterial 2-hybrid
interactions.
The relative beta-galactosidase activity of E.cali DHMI strains co-expressing Cya l8 TARpl-2oo and Cya25 -SIc1 , Cya 25 -Slc2, Cya25 -Sccl or Cya25 -Mcsc. Activity is expressed
as Miller Units after subtraction of the background Cya25 -Empty: Cya l8 -Empty
interaction. Data is representative of multiple trials.

57

Interaction of SIc] with TARP from other Chlamydiae.
SIc 1 is highly conserved between chlamydial species, but there is a complete lack
of amino acid similarity between the N-termini of different chlamydial TARPS.
Alignment of the secondary sequence of the N-terminal200 amino acids ofTARP from

Ctrachomatis L2, Cmuridarum (MoPn), Ccaviae (GPIC), and C pneumoniae with the
bioinformatics program ClustalW indicated conserved and semi-conserved features
among the sequences (Figure 15). Several hydrophobic sites (in red) were spatially
conserved between TARPs, and closer inspection reveals that these hydrophobic sites are
flanked by conserved threonines and serines. However these features are conserved only
through the N-terminal 100 amino acids, indicating a possible chaperone binding site
within these TARPs. This alignment led us to believe that SIc 1 from the L2 serovar
could possibly interact with the other chlamydial TARPS.
I first chose to look at the localization of putative chlamydial chaperones to full
length Chlamydia caviae (GPIC) TARP due to its ability to form aggregates in
mammalian cells. Full length TARP contains C-terminal actin-nucleating domains that
are prone to aggregation and forms a characteristic string-of-pearls pattern when overexpressed in mammalian cells. I was able to acquire the GPIC-GFP-TARP vector
encoding a C-terminal GFP (green fluorescent protein) from the Hackstadt lab at Rocky
Mountain Laboratories. The three putative chlamydial chaperones SIc 1, Sccl, and CT663
were PCR-amplified from L2 genomic DNA and subcloned into the Invitrogen
pENTRIDITOPO entry vector (Figure 16). The attLl and attL2 recombination sites on

this vector allow for recombination into a number of Destination vectors with the
homologous sites attR and attB. For mammalian expression with an N-terminally fused
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Mcherry protein I recombined the chaperones from the entry vector into pDEST-NMcherry (Figure 16). This allowed us to look for co localization of the red chaperones
with green aggregates of GPIC TARP.
The vectors GPIC-GFP-TARP and Mcherry-gus, Mcherry-Slc1, or Mcherry-Slc2
were co-transfected into Cos-7 cells and the co-localization of recombinant proteins was
visualized by confocal microscopy (Figure 17). While the host cytosolic protein, gus
localized some with TARP aggregates, this is probably just due to bleed-through from the
green channel into the red channel. Slc2 localized to the T ARP aggregates to the same
extent as gus indicating a negative result for interaction. However, SIc 1 overwhelmingly
co localizes with T ARP aggregates in this assay. Of the two putative chaperones, only
SIc! was specifically recruited to TARP, confirming it as the specific type III chaperone
for TARP and indicating that SIc1 can interact with the N-terminus ofTARP from
multiple chlamydial species.
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Figure 15. Amino acid alignment of the N-terminus of TARP from different
pathogenic Chlamydiae.
The N-terminal200 amino acids ofTARP from C caviae (GPIC), C pneumoniae (CPn),
C trachomatis (L2), and C muridarum (MoPn) were aligned with clustalW. Residues in
red indicate regions of conserved hydrophobicity, while light blue indicates conserved
residues.
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Figure 16. Diagram of the recombination vectors used to express chaperones in
mammalian cells.
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Merged

GPIC GFP ~TARP +
MCherry·gus

GPIC GFP-TARP +
Mcherry-Slc1

GPIC GFP ~TARP +
Mcherry-Slc2

Figure 17. Localization of SIc! to full-length C. caviae TARP aggregates
IOOX magnified images from confocal microscopy reveal colocalization of GPIC T ARP
and SIcI in cotransfected Cos-7 cells. Cells were co-transfected with GPIC-GFP-TARP
and Mcherry-gus (host cytosolic protein), Mcherry-Slc 1, or Mcherry-Slc2.

62

I continued to test the two other chlamydial T ARPs for their ability to bind L2
SIc1. Interactions between Cpneumoniae and Cmuridarum TARP with SIc1 were tested
by co-immunoprecipitation with M2 Anti-FLAG agarose fo llowed by immunoblotting.
Addition of SIc 1 and Cpn or Mopn T ARP expression lysates allowed for their interaction
which was confirmed by the presence of both of these T ARP species in the S1c1containing elution fractions (Figure 18).

aFLAG

a6XHIS

Lys FT FW E

SIc1

--

Lys FT FW E

SIc1 + MO.Pn TARP
SIc1 + C.Pn TARP

Figure 18. Pulldown of the N-terminus of C. muridarum and C. pneumoniae TARPs
with SIc1.
Immunoblots of the lysates (Lys), flow-through (FT), final wash (FW), and elution (E)
fractions from M2 Anti-FLAG immunoprecipitated recombinant SIc1 and the N-terminal
200 amino acids of C. muridarum (MoPn) or C. pneumoniae (C.Pn) TARPs are probed
with their respective antibodies.
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CHAPTER IV

IDENTIFICATION AND CHARACTERIZATION OF CHLAMYDIAL

CHAPERONE: CHAPERONE INTERACTIONS

Specific interaction between the chaperone SIc I and TARP prompted us look
deeper into the relationship of this chaperone: effector interaction. Translocation
chaperones typically exist as either as a homodimer or a heterodimer prior to their
interaction with their cognate effectors. Since our negative results for interaction
between Slc2 or Scc I and TARP only included possibly homodimers, I felt it necessary
to see if the formation of SIc2-Slc I or Scc I-SIc I heterodimers could contribute to TARP
binding. I chose to characterize all possible chlamydial chaperone dimers to reveal any
interactions that could be important for binding with TARP and other chlamydial
effectors.

Discovery of chlamydial chaperone: chaperone pairs
Therefore, I investigated the ability of SIc I to form homodimers with itself or
heterodimers with either SIc2 or Scc I using both co-immunoprecipitation and bacterial
two-hybrid techniques. As before, I are taking advantage of separate recombinant tags on
the proteins to purify protein complexes and to detect the protein composition of these
complexes by Western blot analysis. I first wanted to detect whether SIcI can interact
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with itself or with other chaperones so I employed M2 Anti-FLAG agarose and Anti-Stag resin to purify chaperone dimers.
By co-immunoprecipitating Flag-tagged SIcI (Slel-F) with S-tagged SIcI (SIcIS) on M2 Anti-FLAG beads, I was able co-elute them from the beads and thus
demonstrate that Slel can multimerize with itself (Figure 19). However I could not
detect any co-elution of SIc2-F with SIcI-S following immunoprecipitation on M2
agarose, indicating a lack of interaction between the two proteins. Similarly, I was also
able to detect an interaction between SIcI-S and Slcl-F by co-immunoprecipitation with
S-Rek resin, but not between Sccl-S and SIcI-F (Figure 20). In both coimmunoprecipitation assays detection of the SIcI: SIcI interaction was minimal. This is
not surprising considering the fact that many known type III secretion chaperones in
other bacteria preferentially form dimers in solution, leaving few monomers around for
potential dimer formation in our assay.
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as-tag

aFLAG
FT

W1

FW

E

FT

W1

FW E

SIc1 ~ S
Slc1-F
Slc1-F + Slc1 -S

Slc2-F
Slc2-F + Slc1-S

Figure 19. Pulldown of FLAG-tagged SIc1 and Slc2 in the presence of S-tagged SIc1.
Irnmunoblots of the FT (flow-through), WI (first wash), FW (final wash), and E (elution)
fractions following M2 Anti-FLAG co-irnmunoprecipitation of FLAG-tagged chaperones
(SIc1-F or Slc2-F) in the presence or absence of S-tagged SIc1 (SIc I-S) from coexpressed BL21 E. coli lysates were detected with aFLAG or as-tag antibodies,
respectively.
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Slc1-F
Scc1-S
Scc1 -S + Slc1-F

Figure 20. Pulldown of SIc1 in the presence of Scc1.
Immunoblots of FT, FW, and E fractions following S-Rek resin immunoprecipitation of
Sccl-S in the presence or absence of Slcl-F were detected with antibodies against their
respective tags .
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Therefore I continued to investigate these interactions by E.coli 2-hybrid analysis,
testing all possible chaperones: chaperone interactions. I was able to detect interactions
between Cyal8-Slci :Cya2s-SlcI, CyaI8-Mcsc: Cya25-Mcsc, and CyawSlc2:Cya2s-Sccl
by blue and fuchsia colonies on X-gal and McConkey plates, respectively (Figure 21).
The Mcsc:Mcsc and Slc2:Sccl interactions had been previously identified in a recent
yeast-two hybrid study [49]. I tested the expression of the CyawSccl and Cya2s-Slc2
recombinant proteins to try to understand why the reciprocal 2-hybrid didn't indicate
interaction, and was able to detect expression of both by coomassie staining (data not
shown). All other chlamydial chaperone: chaperone interactions were similar to the
negative control, and did not produce an obvious color change to blue or fuchsia on
indicator media.
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Figure 21. Bacterial 2-hybrid interactions between chlamydial chaperones.
LB + X-gal + IPTG (left) or McConkey + maltose (right) agarose plates indicate
interaction between co-expressed Cya15 or Cya18 fused chlamydia) chaperones in the
cya deficient E coli strain DHMI. Upregulation of the lactose and maltose operons
results from fusion-protein interaction and is indicated by blue or fuchsia bacteria.
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Quantitative analysis of the

~-galactosidase

activity of the Cyals-ehaperone I

Cya2s-chaperone co-expressing strains indicated a very strong interaction between CyalSMcsc and Cyals-Mcsc, whereas the SIcI :SIc1 and SIc2:Scci interactions were stronger
than the background chaperone: chaperone interactions (Figure 22). Other chaperone:
chaperone interactions were higher than background levels but still lower than the
interactions that had been previously confirmed on indicator plates. Taken together, these
bacterial 2-hybrid data indicate a novel SIc I-Slc1 interaction and confirms the previous
Mcsc-Mcsc and Slc2:Scc1 interactions that were discovered in a recent yeast 2-hybrid
study. All together the co-immunoprecipitation and bacterial 2-hybrid results indicate that
SIc I forms homodimers, but not heterodimers. Given our previous findings that TARP
does not interact with Sec1 or SIc2, it is likely that only Sici homodimers interact with
TARP.
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Figure 22. Quantitative analysis of bacterial2-hybrid chaperone: chaperone
interactions,
The relative beta-galactosidase activity of E.coli DHMI strains co-expressing the
recombinant Cya 18-chaperones and Cya25 -cha~erones. Activity is expressed as Miller
Units after subtraction of the background Cya 5-Empty: Cya l 8-Empty interaction. Data is
representative of multiple trials.
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Determination of the molecular composition of ScI homo-complexes
I expect the apparent SIcI :SIcI interactions shown by co-immunoprecipitation
and bacterial2-hybrid analysis was a result of the formation ofhomodimers, however the
rare case of trimer and tetramer forms of type III chaperones have also been observed to
interact with type III effectors in other bacteria. I chose to detect all native SIc1 complex
forms by stabilizing their interaction with a crosslinker and separating the complexes on
an SDS-PAGE gel. Since I wanted to crosslink M2-Anti-FLAG agarose purified SIc1 in
PBS, I chose to use a hydrolysable crosslinker that could be reduced in the presence of pmercaptoethanol (BME), but not in its absence. In addition I wanted to use a crosslinker
that would react with the primary amines (mostly N-termini) of purified proteins. The
compound DTSSP binds cysteines and primary amines at both ends and has been
modified from its original non-hydrolyzable form, DSP, to be able to dissolve and react
in solution. (Figure 23) Crosslinking of purified FLAG-SIc 1 with the hydrolysable
DTSSP reagent revealed the ability of this protein to form a dimer in the absence of the
crosslinker; this dimeric complex was able to withstand denaturation in the SDS-PAGE
gel (Figure 23). In fact, purified SlcI that was reduced (BME) and heated to 90°C, but
not crosslinked still showed faint dimerization at the expected ~40 kDa size. The
addition a small concentration of crosslinker (0.25 mM) revealed a higher molecular
weight SIcI complex with a size

(~60

kDa) consistent with trim eric species. Since non-

crosslinked, non-reduced purified SIc 1 readily migrated to a dimer-sized position on a
non-reducing SDS-PAGE gel it is clear that SIc1 forms stable dimers.
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Figure 23. Stabilizing SIc1 complexes by the crosslinker DTSSP.
Multimerization of Slcl. (Top) Chemical structure of the crosslinker 3,3' -Dithiobis
(sulfosuccinimidylpropionate (DTSSP). (Bottom) An immunoblot of ~-mercaptoethanol
(~ME), mock-treated (-), or 0.25 mM DTSSP crosslinked (+) purified SIcl was probed
with aFLAG antibody following separation in 12% SDS-PAGE gel under non-reducing
conditions.
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While I was able to detect dimerization of SIc 1 by crosslinking, the presence of a
trimeric species required independent confirmation using gel filtration chromatography,
which is a more gentle analytical technique that did not requiere crosslinking. Upon
purification of SIc I-FLAG with M2 Anti-FLAG agarose, I loaded 50 III of 100 ng/ml
purified SIcl into a Superdex 200 10/300 GL column in PBS. The column washes the
protein through sepharose gel with additional PBS. Larger species get stuck in the gel
sooner, and thus get eluted from the column first. Prior to elution of 500 III fractions
along the length of the gel, the relative abundance of the protein is detected at a
wavelength of 280 nm.
The relative abundance of protein in each of the eluted fractions is shown on the
y-axis, while the relative size of each species (peak) is indicated by the elution fractions
on the x-axis. Each elution fraction was monitored for SIcI content by Western blot.
Higher molecular weight complexes are eluted earlier. Only one prominent peak was
detected for the SIcI complex and when compared to known molecular weight standards
in PBS, it was determined to be ~40 kDa in size (Figure 24). SIc1 was detected in the
TCA-precipitated elution fractions under the dimeric peak by immunoblotting.
Crosslinking and gel filtration of purified SIc 1 indicates that it preferentially forms
homodimers, indicating that this is the form it likely takes when interacting with TARP.
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Figure 24. Detection of native SIc1 species by gel filtration chromatography
The relative abundance of native M2-purified SIc1 complexes were detected and eluted in
500 ul fractions by gel filtration chromatography. An immunoblot of trichloracetic acid
(TCA)-precipitated fractions was detected with aFLAG antibody.
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CHAPTER V

FUNCTIONAL DETERMINATION OF SLCI IN THE TRANSLOCATION OF
TARP BY HETEROLOGOUS TYPE III SECRETION SYSTEMS

TARP: SIc1 complexes indicate the expected 2:1 stoichiometry o/type III chaperone:
effector interactions
I was able to detect a complex formed between SIc I and TARP by detection of a
shift in complex size between purified recombinant TARP and TARP co-expressed in the
presence of SlcIon a silver-stained native gel and on its corresponding 6XHIS-probed
immunoblot. Since native gels separate proteins based on their shape and size, it is
difficult to extrapolate an approximate molecular weight of the complex (Figure 25).
To gain some insight into the composition of the complex formed by TARP and
SIc I, a similar chromatography approach was used to analyze purified HIS 6-TARP 1-200
and the HIS6-TARpl-200 /SIcI-FLAG complex. The chromatography conditions produced
readily identifiable peaks for HIS 6-TARp l-200 from SIc1-FLAG quite easily (Figure 26).
To determine the approximate size of the protein complex formed by T ARP and
SIcI, the Ni-Nta agarose eluates from lysates containing co-expressed HIS6-TARpl-200
and SkI-FLAG were subjected to gel filtration chromatography. Ni-Nta purified protein
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from the lysate containing HIS 6-TARp l -200 was used as a reference control. The Sic 1 and
TARP content of the co-expressed elution fractions was detected with antibodies against
their respective tags by Western blot. Since the co-expressed complex was purified with
Ni-Nta agarose, I expect the sample to contain both monomeric TARP and TARP in a
complex with Sic 1. Here I see that TARP-containing elution fractions correspond to a
peak between 13.9 kDa and 29 kDa and a peak >75 kDa, while Slcl is present only in the
elution fractions corresponding to the >75 kDa peak. These sizes are in agreement with
monomeric TARP and a l:2 complex of TARP to SIc 1. Taken together with our SIc 1
dimerization data, the results indicate that a dimer of the Slcl chaperone forms a complex
with one molecule ofHIS6-TARp l -200 when co-expressed. In order to detect the SlclTARP complex by chromatography, co-expression of Sic land TARP appeared to be
necessary because the addition of pre-purified components failed to produce a similar
>75 kDa-peak (Figure 27).
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Figure 25. Native gel shift ofTARP: SIc! complex
Native purified protein complexes are shown on both silver stain and Western blot. All
protein species from the purified fractions are displayed on the silver-stained Native
PAGE gel on the left. TARP-containing complexes are detected in the identical purified
fractions with u6XHIS antibody on the immunoblot on the right. Arrows indicate the
complex formed under co-expressing conditions.
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Figure 26. Detection ofTARP: SIc1 native complex (coexpressed).
Separation and detection of co-expressed SIc 1: TARP complexes. The relative
abundances of native NiNta-purified TARP I -2oO complexes alone or co-expressed with
SIc1 were detected and eluted in 500 ul fractions (top) by gel filtration chromatography.
Immunoblots of the TeA-precipitated elution fractions were detected with a6XHIS and
aFLAG antibodies (bottom).
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Figure 27. Detection ofTARP: SIc1 native complex (Combined).
The separation and detection of M2-purified Sic 1 (Red), Sic 1 +TARP (Blue), or Ni-Ntapurified TARP (Green) was achieved by gel filtration chromatography. The peaks on the
chromatogram correspond to the molecular weight standards (top). The relative
abundances at A280 are indicated by the y-axis and the corresponding immunoblots of
the 500).!1 fractions on the x-axis were TeA-precipitated and detected with a6XHIS and
aFLAG antibodies.
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Translocation of TARP by heterologous type III secretion systems
While the biochemical data suggests that SIc 1 interacts with TARP in a fashion
typical of type III chaperone: effector complexes, I desired to know what role SIc1 plays
in TARP translocation by the chlamydial type III secretion apparatus. Unfortunately,

Chlamydia's lack of a genetically tractable system prevented us from directly testing
SIc 1's role in TARP's translocation from the chlamydial EB into mammalian epithelial
cells. Fortunately, I was able to express our recombinant chlamydial proteins in the
pathogenic bacteria Yersinia enterocolitica, Enteropathogenic E. coli (EPEC), and

Salmonella typhimurium and detect TARP' s translocation through their heterologous type
III secretion apparatuses into Hela cells.
To accomplish this, I took advantage of an existing translocation assay that
involved expressing possible effectors in the pCX340 vector that C-terrninally fuses them
to enzymatically active p-Iactamase, and the chaperones were cloned into an arabinoseinducible expression vector pBAD I8-Cm (Figure 28). The chaperones were amplified
from C. trachomatis L2 genomic DNA by PCR (Figure 29) and cloned into the KpnI and
XbaI sites on the vector. A KpnI site was added downstream of the TARp l -200 open
reading frame in the pET200-TARp l -2oO vector by SLIM PCR (Figure 30), while TARP
was cloned into the NdeI and KpnI sites ofpCX340 (Figure 31).
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Figure 28. Diagrams of the bacterial expression vectors pBAD18-Cm and pCX340.
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Figure 29. Cloning chlamydial chaperones into the pBAD18-Cm vector
(Top) Insert PCRs ofCT043 and Mcsc open-reading frames with flanking XbaI and Seal
sites. (Bottom) Colony PCRs from chloramphenicol-selected pBAD I8-chaperone
transformants.
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Figure 30. Adding a KpnI site to the pET200-TARP200 construct by SLIM peR.
(Top) Si te-directed Lipase-Independent Mutagenesis (SLIM) based PCR was performed
to add a KpnI site downstream of the TARP200 open reading frame in the pET200TARP200aa vector and the PCR product is displayed here on a 0.7% Agarose gel.
(Bottom) pET200-TARP200aa-KpnI plasmid DNA prepared from kanamycin-selected
Bl21 star E.coli transformants were checked for the presence of a KpnI site by restriction
digest as displayed here on a 0.7% Agarose gel.
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Figure 31. Cloning TARP into the pCX340 vector.
(Top) The TARP200aa open reading frame was digested with Kpnl and NdeI from the
pET200-TARP200 vector and pCX340 was double digested as well prior to ligation as
indicated here on the 1 % Agarose gel. (Bottom) Colony PCR was performed on
tetracycline-selected transformants and separated on a 1.2% Agarose gel.
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Upon contact with mammalian cells, the bacteria will translocation their type III
effectors into the host cell. Treatment of the HeLa cell mono layers with CCF21AM, a
coumarin molecule bound to hexane by a 0-lactam ring, following infection allows for an
especially innovative fluorescence assay that takes advantage of the fact that the intact
substrate fluoresces at 520 nm and the cleavage product, coumarin, fluoresces at 450 nm
(after excitation at 410 nm). The presence ofTEMI-fused bacterial effectors in the host
cell is reflected in the cleavage of the b-Iactam ring to release the coumarin molecule,
which I can measure its fluorescence at 450 nm. Thus I can detect fluorescence
resonance energy transfer, (FRET) of the intact molecule in the green spectrum at 520
nm, while I can detect cleavage of the substrate as a loss of FRET in the blue spectrum at
450 nm. A diagram of the basis of this assay is shown in Figure 32.
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Figure 32. Diagram of the CCF2/AM fluorescence-based translocation assay
In the bacterial cell, ~-lactamase fused TARP is expressed from the pCX340-TARP
vector. Two hours post-infection of He La cell monolayers, cultures are treated with
CCF2 /AM, a molecule that undergoes FRET (Fluorescence Resonance Energy Transfer)
when excited at 410 run and emits fluorescence in the green spectrum at 450 run.
Translocation of ~-lactamase fused TARP by the bacterial Type III Secretion System
(T3 SS) into the eukaryotic cell and subsequent cleavage of the ~-lactam ring portion of
CCF2 /AM results in a loss of FRET and an alternate emission of fluorescence in the blue
spectrum at 450 nm.
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The Yersinia ysc family type III secretion system is encoded on its virulence
plasmid[63]. The type III secretion system from Yersinia pseudotuberculosis has been
previously used to express and secrete chlamydial translocators and effectors, including
TARP, into low-calcium media[38, 41,150]. I was also able to detect TARP secretion
into media by wild-type Yersinia enterocolitica similar to levels of secretion of the
Yersinia effector, YopH (Figure 33).

However, Yersinia strains have not been tested for their ability to translocate
chlamydial proteins into eukaryotic cells. I chose to utilize the type III secretion system
of Yersinia enterocolitica to determine the role of Slcl in the secretion and translocation
of TARP. Based on previous findings, I expect that some TARP will be secreted and
possibly translocated in the absence of its cognate chaperone [42]. However, our
interaction studies indicate that the chaperone Slc 1 binds TARP in a fashion typical of
export chaperones convincing us that SIc1 will enhance TARP's interaction with the type
III secretion apparatus and thus increase the amount TARP secreted or translocated by

the Yersinia enterocolitica type III secretion system.
Wild type and type III ATPase (Y scN) knockout strains of Y. enterocolitica expressing
TARP ±-SIc1 were allowed to infect HeLa cell monolayer for 2 hours prior to CCF21AM
treatment. A loss of FRET (p-Iactamase-mediated cleavage) to FRET (no cleavage) ratio
was used to detect translocation. Translocation of the positive control, YopH was
detected at a fluorescence ratio of ~0.8, and the negative control empty vector indicated
at ratio ofless than 0.1 (Figure 34). I was able to detect SIc1-mediated translocation of
TARP as indicated by the ratio of 0.67 by co-expressing bacteria and 0.43 from TARPonly expressing bacteria. Because the YscN knockout strains were unable to translocate
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any effectors, I can be absolutely positive they are being translocated through the

Yenterocolilica type III secretion needle.
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Figure 33. Secretion of HIS6-T ARP l -200 by the Yersinia enterocolitica type III
secretion system. Immunoblots of TCA-precipitated Yersinia enterocolitica culture
supernatants (S) and whole cell pellets (P) under type III secretion inducing conditions (Ca) or repressing conditions (+Ca) were probed with ~-lactamase mAb. Secretion was
tested by wild-type (WT) or type III secretion knockout (dYscN) Yersinia enterocolitica
strains.
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Translocation of TARP by the Yersinia enteroco/itica T3SS
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Figure 34. Translocation of T ARP by Yersinia enterocolitica.
The fluorescence ratio of cleaved CCF2 /AM substrate (450 nm) to uncleaved substrate
(520 nm) indicates the relative translocation of B-Iactamase fused effectors by the ysc
type III secretion system of Y enterocolitica. Wild-type (WT) and the Type III ATPase
yscN knock-out (T3KO) strains bearing the B-Iactamase fusion vector pcx340 with or
without pBAD-Slcl were allowed to infect HeLa cells prior to treatment with CCF2/AM
substrate and fluorescence detection.
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I next used the Enteropathogenic Escherichia coli (EPEC) to test the translocation
of TARP. To date there has been no evidence of secretion of chlamydial proteins by the
EPEC type III secretion ofTARP. However, EPEC is known to translocate the type III
effector Tir that has very similar function in vivo as TARP. They both induce massive
cytoskeleton rearrangement to ensure close attachment and survival of the bacteria.
Furthermore alignment of type III secretion chaperones has revealed that Tir's cognate
chaperone CesT has very similar secondary structure as SIc 1. Therefore I thought it
likely that the EPEC type III secretion could translocate TARP in the presence of its
cognate chaperone SIc1.
EPEC attaches to epithelial cells and begins to translocate its effectors as soon as
30 minutes post-infection. I was able to detect translocation of the EPEC effector EspH
as a fluorescence ratio of 1.5 after 1 hour of infection. Using the same infection
conditions I was unable to detect any chaperone-dependent or -independent translocation
of T ARP. (Figure 35), and lengthening the duration of infection did not change this
negative result (data not shown).
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Fig 35. Translocation of TARP by Enteropathogenic E. coli
The fluorescence ratio of cleaved CCF21AM substrate (450 run) to uncleaved substrate
(520 run) indicates the relative translocation of ~-lactamase fused effectors by the type III
secretion system of Enteropathogenic E. coli (EPEC). Wild-type (WT) and the Type III
ATPase escN knock-out (T3KO) EPEC strains bearing the ~-lactamase fusion vector
pcx340 with or without pBAD-Slcl were allowed to infect HeLa cells prior to treatment
with CCF21AM substrate and fluorescence detection.
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Salmonella typhimurium contains two functional type III secretion systems that
are temporally regulated and are responsible for translocating distinct sets of effectors
into epithelial cells. The SPI -1 (Salmonella pathogenicity island-I) type III secretion
system translocated effectors upon contact with host cells to induce uptake of Salmonella
into endocytic vesicles. After complete engulfment of the bacterium, it switches to
secretion of effectors involved in maintaining its Salmonella-containing vesicle (SCV)
and in redirecting host cell vesicle trafficking to ensure its intracellular survival[63].
Because the SPI -1 T3 SS is responsible for secreting proteins involved in invasion of
eukaryotic cells, it is an attractive choice for testing TARPs translocation. However, the
SPI-2 system resembles that of Chlamydia because of its ability to secrete from an
intracellular vesicle indicating that it also is worth trying as a heterologous secretion
system.
As indicated by the fluorescence ratios of infected mono layers, the Salmonella
SPI-l secretion system was unable to translocate TARP under any conditions (Figure
36), but the SPI-2 system seemed to minimally translocate TARP in a chaperoneindependent manner, but achieved efficient translocation of TARP in the presence of its
cognate chaperone SIcl (Fig 34). However the high ratios for the

~-lactamase

only

(pcx340-Empty) translocation casts some doubt on the reliability of this assay under SPI2 conditions. Furthermore, this assay has remained untested for translocation during
intracellular growth (8-12 hours post-infection); instead its use has been for detection of
translocation of substrates immediately after attachment (1-3 hours post-infection).

93

Translocation of TARP by Salmonella

E
c:

1.2

o

C\I

~

1

c:
o

0 .8

-=:t

0.6

E

10

r-""'"

Q)

o
c:
Q)
o
If)

...o

Q)

::J

u:::

0.4
0 .2

o

-

,......

,....,

r-""'"

-

-.

Figure 36. Translocation ofTARP by Salmonella typhimurium SPI-l and SPI-2
The fluorescence ratio of cleaved CCF2 /AM substrate (450 run) to uncleaved substrate
(520 run) indicates the relative translocation of ~ - lactamase fused effectors by the SPI-l
and SPI-2 type III secretion systems of Salmonella typhimurium. Wild-type (WT)
Salmonella strains bearing the ~ - lactamase fusion vector pcx340 with or without SIcI
were allowed to infect BeLa cells prior to treatment with CCF21AM substrate and
fluorescence detection. SPI- l mediated translocation was detected 2 hours post-infection,
while SPI-2 mediated translocation was detected 10 hrs post-infection .

94

The differences in TARP translocation by different heterologous type III secretion
systems is likely to due to the inability of the cytoplasmic components from other type III
secretion systems to recognize the TARP-Slcl complex. To gain insight into this
possibility, I analyzed the relatedness of the chlamydial type III A TPases CdsN and FliI
with the type III A TPases from Salmonella, Yersinia, and EPEC. The amino acid
sequences of these paralogs were aligned with ClustalW and the resulting alignments
were organized into unrooted dendograms (Figure 37). The CdsN tree indicates that

Yersinia type III ATPase YscN and the SPI-2 ATPase SsaN are similar to the nonflagellar chlamydial ATPase, while the A TPases from the SPI -1 and EPEC are less
closely related, supporting our findings that Yersinia type III system and the Salmonella
SPI-2 system could both recognize the TARP: chaperone complex and subsequently
translocate TARP into HeLa cells. Furthermore, phylogenetic analysis indicates that the
chlamydial flagellar type III ATPase FliI is more similar to the EPEC and SPI -1 nonflagellar ATPases than to relevant ATPases in Yenterocolitica and the Salmonella SPI-2
systems.
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Figure 37. Phylogenetic analysis of multiple type III components from bacterial
pathogens.
Unrooted phylograms were created from ClustalW-generated multiple sequence
alignments of the C pneumoniae (cpn) and Ctrachomatis (ctr) ATPases CdsN (top) and
FliI (bottom) with the relevant ATPases from S. typhimurium (stm), and
Enterropathogenic E.coli (ecg). Orthologs were identified for comparison by the Kyoto
Encyclopedia of Genes and Genomes (KEGG).
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TABLE 5. STRAINS AND PLASMIDS USED IN THIS STUDY
Strains
Top 10 (DHI0B)
BL21 (OE3A)
OHMI
E2348/69

Description
E.coli high-level propagation
E.coli high-level expression
Adenylate cyclase deficient E.coli
Wild type EPEC 0127:H6

ICCI92
12023s
HHI09
MRS40(p YV 40)
MRS40(pMSL41 )

EPEC E2348/69~escN
Wild type Salmonella enterica typhimurium
ssaV::aphT in 12023 (Kmr)
Yersinia enterocolitica, ampicillin-resistant derivative
Y scN ATPase knockout of MRS40

Reference
Life Technologies
Life Technologies
Karimova,G (1995)
Levine et al (1978)
Garmendia et al
(2004)
NCTC
Deiwick et al.(1999)
Sory,M.P. (1994)
Sory,M.P. (1995)

full length C.caviae TARP in pEGFP-CI vector

Lane et aI, (2008)

pCONA 6.2 derived vector with N-terminal Mcherry
N-Mcherry-pOEST expressing SIcI
N-mcherry-pOEST expressing S1c2
N-mcherry-pDEST expressing Sccl
directional TOPO expression vector
directional TOPO expression vector

Scott Grieshaber
This study
This study
This study
Invitrogen
Invitrogen

directional TOPO entry vector for LR recombination
bacterial expression destination vector (LR)
pETI0l expressing SIcI-FLAG
pETI0l expressing S1c2-FLAG
pET200 expressing N-terrn 200aa ofL2 TARP
pDEST-56 expressing Sccl-FLAG
pOEST-56 expressing S1cl
E.coli 2-hybrid vector - cya fragment 18 fusion
E.coli 2-hybrid vector - cya fragment 25 fusion
E2H -cya-18 fragment fused to Nterrn 200aa TARP
E2H -cya-18 fragment fused to Nterm 200aa Tir
E2H -cya-18 fragment fused to CT043
E2H -cya-18 fragment fused to CT088
E2H -cya-18 fragment fused to CT260
E2H -cya-18 fragment fused to CT663
E2H -cya-25 fragment fused to CT043
E2H -cya-25 fragment fused to CT088
E2H -cya-25 fragment fused to CT260
E2H -cya-25 fragment fused to CT663
E2H -cya-25 fragment fused to CesT

Invitrogen
Novagen
This study
This study
This study
This study
This study
Karimova,G (1998)
Karimova,G (1998)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

Plasmids
pEGFP-TARP
N-MCherrypOEST
pMch-Slcl
pMch-Slc2
pMch-Sccl
pETI0l
pET200
pENTR-O/SDTOPO
pET56-0EST
pSlcl-FLAG
pS1c2-FLAG
pTARP200
p56-Sccl
p56-S1cl
pUT18C
pKT25
pI8C-TARP
pl8C-Tir
p18C-CT043
p18C-CT088
p18C-CT260
p18C-CT663
p25-CT043
p25-CT088
p25-CT260
p25-CT663
p25-CesT
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pCX340
pBAD-TOPO
pBADl8
pCX340TARP200
pCX340-PipB2
pBAD-CT043
pBAD-CT088
pBAD-CT260
pBAD-CT663

TEMl fusion, IPTG inducible
Arabinose-inducible promoter
Arabinose-inducible promoter

Charpentier (2004)
Invitrogen
Guzman (1995)

N-term 200aa ofTARP fused to TEMl
N-term 200aa ofPipB2 fused to TEMl
pBAD-TOPO with CT043-FLAG insert
pBADl8 with CT088-FLAG insert
pBAD-TOPO with CT260-FLAG insert
pBAD18 with CT663-FLAG insert

This study
This study
This study
This study
This study
This study

TABLE 5. PRIMERS USED IN THIS STUDY
Primers
AJBIF
AJBIR
AJB2F
AJB2R
AJB3F
AJB3R
AJB4F
AJB4R
AJB5R
AJB6FT
AJB6FS
AJB6RT
AJB6RS
AJB7FT
AJB7FS
AJB7RT
AJB7RS
AJB8F
AJB8R
AJBIOF
AJBIOR
AJBl3R
AJBl4F
AJBI4R
AJBl5F
AJBl5R
AJBl6F
AJBI6R
AJBI7F
AJBI7R
AJBI8F
AJBI8R
AJBl9F

Sequence 5' => 3'
CACCATGTCCAGGCAGAATGCTGA
TCACTTGTCATCGTCGTCCTTGTAGTAGCACGGATTCCTGCGGTA
CACCATGTTGGAAAAATTGATAAAGAATTTTGTGGCG
TTACTCCTGCTCCGTTTTACTTAGTCTAAATC
CACCATGCAAAATCAATTTGAACAACTC
ATCGATTTACTTGTCGTCATCGTCCTTGTAGTCCAGGTGATACAT
CACCATGACGAATTCTATATCAGGTGATC
TTATCCTACGGTATCAATCAGTGAGCT
TTATGCACGGATTCCTGTGGAGG
CCTTCACCAAGGGTACCTCAACGATCCGGCTGCTAACAAAGCC
CCGGCTGCTAACAAAGCC
TCGTTGAGGTACCCTTGGAGGAGCCTCTTAGAGA
CTTGGAGGAGCCTCTTAGAGA
CGATTAAATAAGGAGGAATAACATATGACGAATTCTATATCAGGTGATC
ACGAATTCTATATCAGGTGATCAACCTA
CATATGTTATTCCTCCTTATTTAATCGCGATACATTAATATATACCTCT
CGATACATTAATATATACCTCTTTAATTTTTAATAATAAAG
ACCATGGCCTCCAGGCAGAATGCT
TTATTAGTCCTTATCGTCATCGTCCTTGTAATCTGCACGGATTCTGCT
ACCATGGCCACAACGTGGACTTTGAATCAC
TTATTAGTCCTTATCGTCATCGTCCTTGTAATCAGGCTCTAGCTGATCGGAT
GAACTAACGTATGGAGAAAGGTACCCAAGCTTCCAGCAACGGCTT
CGTAGGACGCATATGAACTTATCATTAAGCGAT
TGAATCTCAGGTACCGCGGCTGCTGAGTTC
TAGCATCGGGTACCGATGACGAATTCTATATCAG
CGTAGCTATCGATGAGCCACTTGTGCTAGA
GTTACGATCTAGAGATGCCTATTGGTAACCTTGGTAATA
CTAGTGCAGGTACCTTACGTATCAACGTCCTT
TTACGTATTCTAGAGATGTCCAGGCAGAATGCT
GCATTAGTGGTACCCTTATGCACGGATTCCTGC
TGTACCGTATTCTAGAGATGCAAAATCAATTTGAAC
TGCTATCGGTACCTTACAGGTGATACATACCT
TTACGTATTCTAGAGATGACAACGTGGACTTTG
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AJBI9R
AJB20F
AJB20R
AJB21F
AJB21R
AJB22F
AJB22R
AJB23F
AJB23R
AJB24F
AJB24R
AJB25F
AJB25R

GCATTAGTGGTACCCCTAAGGCTCTAGCTGATC
GGACGGACTCTAGAGATGTTGGAAAAATTGATA
GCATTAGTGGTACCCTTACTCCTGCTGCGTTTT
TAACAGTAGGTACCTTATCTTCCGGCGTA
TTACGTATTCTAGAGATGTCATCAAGATCTGAAC
CATTATTCTAGAGATGTCCAGGCAGAATGCTGAG
TTGCTAGTACCCGTTATGCACGGATTCCTGCTGG
CATTATTCTAGAGATGCAAAATCAATTTGAACAA
TTGCTAGTACCCGTTACAGGTGATACATACCTAG
CATTATTCTAGAGATGACAACGTGGACTTTGAAT
TTGCTAGTACCCGTTAAGGCTCTAGCTGATCGGA
CATTATTCTAGAGATGTTGGAAAAATTGATAAAG
TTGCTAGTACCCGTTACTCCTGCTCCGTTTTCTT
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DISCUSSION

Many intracellular bacterial pathogens use specialized secretion systems to
translocate effectors into eukaryotic cells and in turn these effectors recruit, modify, or
hijack cellular components to the benefit of the bacterium. Effectors of bacterial type III
secretion systems have been reported to be involved in remodeling the eukaryotic
cytoskeleton, altering the immune response, hijacking trafficking vesicles, disrupting
cell-to-cell junctions, and causing cytotoxicity[ 63].
Survival and pathogenesis of Chlamydia spp. is entirely dependent on its ability to
invade mammalian epithelial cells and develop a unique niche that is conducive to
intracellular growth and replication. Translocation of effectors by a type III apparatus is
a major strategy for Chlamydia entry, inclusion formation, and survival in eukaryotic
cells[46, 84, 85]. Recruitment of host kinases and actin, in addition to activation ofRac
and actin-poylmerization aid in endocytosis, and are functions attributed to the type III
invasion associated effector TARP[42, 66, 67, 69, 132]. Chlamydia trachomatis
urogenital, lymphogranuloma, and ocular strains synthesize TARP homologs that contain
three functional domains: tyrosine-rich repeats for recruitment of host kinases and
subsequent Rac activation, a proline-rich aggregating domain, and actin-nucleating WH2like domains.
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Detected and tyrosine-phosphorylated in host cells within minutes after cell
contact, TARP translocation is essential for the efficient uptake of C. trachomatis EBs.
TARP homologs in C.pneumoniae, C.caviae, and C.psittaci do not contain tyrosine-rich
repeat domains, but they are still able to invade host cells. In addition the WH2-like
domains are sufficient to nucleate actin in host cells, which are also important for
infection[70, 71]. This redundancy between TARP domains indicates another possible
function for C. trachomatis TARP tyrosine-phosphorylation during chlamydial infection.
It has been suggested that the tyrosine phosphorylation may help ensure specific uptake

pathways that prevent phagolysosomal fusion. This theory has been supported by the
detection ofTARP localized to the inclusion throughout the developmental cycle[42].
Given TARP's pivotal roles in entry and intracellular survival, I considered
possible type III secretion chaperones that would increase the efficiency of TARP
translocation into host cells. I determined that the chlamydial chaperone SIcI specifically
interacts with TARP and mediates its translocation by the heterologous type III secretion
system of Yersinia enterocolitica. Identification of putative type III related genes in
bioinformatics studies identified three putative chlamydial effector chaperones: SIcl,
Slc2, and Scc 1. Since Class I effector chaperones share the specific secondary structure

a-0-0-0-a-0-0, putative chlamydial chaperones were readily identified by in silico
approaches. Detection of these three proteins in elementary bodies indicated that anyone
of them could be involved in maintaining TARP in a secretion-competent state for
immediate translocation into host cells.
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In other gram-negative bacteria, previously identified type III Class I effector
chaperones demonstrated binding of their effectors adjacent to their N-terminal secretion
signal, usually within the N-terminaI30-130 amino acid range.

Identification of the TARP's cognate secretion chaperone Slcl
I used a direct co-immunoprecipitation approach for identifying a chlamydial
chaperone that could interact with the N -terminal 200 amino acids of C. trachomatis L2
TARP. I was specifically able to co-immunoprecipitate SIcI with TARP in two
independent co-IP approaches. Separate expression of SIc 1 and TARP in E. coli prior to
incubation of their lysates with M2 Anti-FLAG agarose yielded an interaction between
SIc 1 and TARP, but co-expression of these proteins prior to co-immunoprecipitation
greatly increased their ability to interact. This indicates to us that SIc1 may mediate
folding of TARP or prevent its pre-mature interaction with other E. coli components when
expressed in the same bacterium. However, neither co-immunoprecipitation technique
was able to demonstrate an interaction between TARP and the other putative chlamydial
chaperones SIc2 or Scc 1.
One other explanation for the increased interaction between SIc 1 and TARP
during co-expresssion would be that SIcI prevents TARPs degradation or solubility. The
cognate chaperone SycE in Yersinia helps to solubilize its cognate aggregrate-proned
effector YopE[151], and similarly the EPEC chaperone CesT prevents the degradation of
the effector Tir[ 152]. Despite the described ability of many known type III chaperones to
solubilize and stabilize their effectors, I was not able to detect any changes in solubility
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or stability of T ARP when expressed in the presence or absence of its chaperone (data not
shown).
One caveat of detecting chaperone: TARP interactions in Ecoli lysates, is that an

Ecoli protein may be mediating the interaction detected between SIc! and TARP. It is
difficult to refute this claim, because attempts to find an interaction between pre-purified
TARP and SIc! were unsuccessful. Because this possible E coli factor did not mediate an
interaction between TARP and Scc! or SIc2, which are predicted to have extremely
similar secondary and tertiary structures as SIC!, I propose that it is highly unlikely for an

Ecoli factor to be so specific for SIcI and TARP.
Our co-immunoprecipitation findings were confirmed by the specific interaction
detected between SIcI and TARP in an adenyl ate-cyclase (cya) based bacterial2-hybrid
system[I48]. Because the readout for interaction of cya-fused target and bait proteins in
this system was the cAMP-mediated up-regulation of the lactose and maltose operons, I
was able to detect interactions in a variety of assays. Both X-gal and McConkey plates
indicated a range of protein-protein interactions from low-affinity (chaperone-effector) to
high affinity (leucine-zipper proteins). While the indicator plates allowed for obvious
qualitative results of chaperone-effector interactions, they were not able to differentiate
between slow and fast growing strains. If allowed to grow long enough, even the
negative control strains would begin to change color on these indicator plates, therefore I
had concerns that any slow-growing strains would not indicate obvious interactions.
To alleviate this problem as well as to quantitatively compare protein-protein
interactions, I employed the

~-galactosidase

assay which not only takes into account the

amount and time of ONPG conversion, but also the total number of bacteria in each
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sample. Compared to co-expression with other chaperones tested in this assay, DHMI

E.coli co-expressing SIcI and TARP converted 2-3 times as much ONPG to the
colorimetric substrate ONP, confirming the bacterial2-hybrid results on indicator plates.

Characterizing all possible chlamydial chaperone-chaperone interactions
The tendency of type III chaperones to dimerize prior to interacting with their
effectors, led us to detect whether SIc 1 tends to form homodimers or heterodimers. From
co-immunoprecipitation assays I was able detect SIcI interactions with itself, but not with
the other putative chaperones Slc2 or Scc1. Since I singly expressed the chaperones prior
to adding the lysates to the M2 Anti-FLAG agarose or S-rek resin, it is likely that SIcI
dimers were formed early, leaving very little monomeric SIcI to interact with other
chaperones. Instead of testing co-expression in the co-IP assays, I thought it best to test
co-expressed chaperone-chaperone interactions in the bacterial 2-hybrid system. In this
system I was able to confirm previous chlamydial chaperone-chaperone interactions as
well as confirm our SIc I-SIc 1 interaction. Obvious interactions on indicator plates
included SIcI-SIcI, Mcsc-Mcsc, and Slc2-Sccl. However, I was not able to detect the
reverse Cyals-Scc1/Cya2s-Slc2 interaction indicating that the dimer formed may only
allow interaction of the 18 and 25 fragments when the dimer is formed in the Cya18-SIc21
Cya2S_Scc 1 orientation and not the other way around. Furthermore, I was able detect
expression of both I8-SccI and 25-SIc2; consequently the lack of bidirectional
interaction was not due to the constructs being problematic.
Quantitative analysis of chaperone-chaperone interactions in the bacterial 2hybrid strains indicated the same positive interactions as on indicator plates, but there
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also seemed to be a low level of interaction between most of the chaperones. The Slc ISle 1 interaction was only 2-fold higher and the Sle2-Scc 1 interaction was only slightly
higher than most of the chaperone-chaperone strains. I speculate that Chlamydia
maintains a low level of interaction between type III class I chaperones to enable the
bacterium to quickly acquire new type III effectors. This is supported by the fact that
Candidata Protochlamydia ameobophilia maintains SycE-like Class I chaperones in the

same gene order as in pathogenic Chalmydia, however the chaperones themselves have
completely diverged in amino acid sequence[22, 29]. In addition, recent studies have
identified species-specific effectors among chlamydial pathogens[84], indicating a
mechanism for the quick selection of new type III effectors for adaptation to new host
cell types must exist. It has been noted in other bacteria that there is little conservation in
sequence or structure of type III effectors, despite the requirement that all effectors must
be adequately unfolded to ensure secretion through the

~4

nM diameter needle[29, 59,

153]. Thus type III chaperones may be necessary to partially unfold disordered regions
in effectors so that they may effectively interact with the type III ATPase[59, 153].
Akeda et al. maintain that the ATPase actually does the majority of unfolding
effectors in addition to providing active (ATP-dependent) separation of effectors from
cognate chaperones[59]. Recent crystallizations of chaperone: effector complexes
support this theory that chaperones only act to locally unfold or reorder the effector at the
chaperone binding domain (CBD). Whether this localized unfolding allows for the
unfolding of the N-terminal secretion signal or makes the secretion signal more
accessible to the ATPase is not clear.
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Besides being unfolded, secretion of type III effectors requires an N-terminal
secretion signal that is possibly recognized by the ATPase. However, this signal is highly
divergent and efforts to predict secretion substrates based on their N-terminal amino acid
composition has remained challenging. Recent studies have used machine-learning
approaches that focused on the N-terminal25 amino acids of known type III effectors to
predict the probability that a protein is in fact an effector[25, 30]. Predicted secretion
signals were mostly disordered, largely hydrophobic, often with polar-hydrophobic-polar
residue patterns, and were serine and threonine-rich. One such prediction program
identified 86 putative C. trachamatis effectors, 24 of which had already been
experimentally confinned to be type III effectors[30].
Considering the small number of possible chaperones, it is clear that not all of
these effectors will require a chaperone for their translocation. Thus a major enigma in
bacterial type III secretion is why some effectors require chaperones while others do not.
In EPEC and Yersinia, a hierarchy of secretion is established in which effectors that have
cognate chaperones are secreted preferentially to those without chaperones[62, 154, 155].
Since few chlamydial chaperone-effector interactions have been detected thus far, I have
no indication as to whether such a hierarchy exists during infection, but it is easy to
imagine how such a hierarchy could playa role in regulating Chlamydia '8 developmental
cycle.
The recently discovered type III secretion chaperone Mcsc was not predicted to be
a Class I chaperone by in silica analysis, but its association with effectors and ability to
form homodimers in a yeast 2-hybrid screen[49] led us to test its ability to interact with
TARP as well as its ability to form heterodimers in our bacterial 2-hybrid assays. I did

106

not detect any interaction between TARP and Mcsc, but the Mcsc-Mcsc co-expressing
DHMI strain had nearly 6 fold higher

~-galactosidase

activity than the Slcl-SIcI

interaction and as much as 10 fold higher than other background chaperone-chaperone
interactions. Mcsc is an atypical Class Ib chaperone that has been shown to have
multiple effectors and also interacts with several type III C-ring components, therefore its
role in Chlamydia infection may differ from the typical effector chaperones and cannot
be compared directly with other Class I chaperones.
Being associated with both type III secretion effectors and cytoplasmic
components of the type III apparatus, the Mcsc dimer has been speculated to playa role
in co-translational secretion of effectors [49]. No evidence has been presented thus far to
suggest the coupling of effector translation and non-flagellar type III secretion in
Chlamydia, nor in other bacteria. However, a model of flagellar secretion coupled with
translation of the FlgM mRNA transcript has been proposed in Salmonella
typhimurium[I56]. In addition to Mcsc's ability to interact with apparatus components,
the Chlamydia non-flagellar type III components have also been shown to interact with
flagellar components[I57]. Thus it is possible that the Chlamydia type III secretion
system is capable of unique mechanisms of regulating substrate translation and
translocation.

Oligomerization state of SIc1 and SIc1: TARP complexes
Further characterization of the SIc I-SIc 1 interaction was detected with crosslinking and gel filtration chromatography. While the cross-linking with DTSSP was only
supposed to stabilize the already formed SIc 1 homo-complexes, I contend that trimeric
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SIc1 species were induced in the presence of the cross-linker. Purified SIcI was highly
concentrated in our samples and separate molecules of SIc I were likely in close enough
contact to become cross-linked. The most revealing aspect of the cross-linking assay was
the finding that SIc I homo-dimers could be detected on a non-reducing SDS-PAGE gel
even without cross-linking treatment.
Gel filtration chromatography only confirmed our hunch that native SIcI forms
stable dimeric species in solution. A single native SIc I complex migrated through the
sepharose column to a position corresponding to a molecular weight of approximately 40
kDa, which is certainly indicative of homo-dimers. However, gel filtration
chromatography is sensitive to both the size and molecular weight of the sample, so I
cannot pinpoint an exact molecular weight with this assay. This approach was also useful
for detecting the native SIc I : TARP complex. I expected to find a complex of a
combined molecular weight of ~ 65 kDa (2 chaperone molecules to I TARP), but the
SIcI and TARP-containing elution fractions corresponded to a size >75 kDa. One reason
for this larger size could be that the complex actually has a stoichiometry of2:2, however
this is unlikely considering the plethora of crystallization data supporting a 2: I
stoichiometry for type III chaperone: effector complexes. Instead I claim that the
partially unfolded TARP in combination with the chaperone dimer has an extended size
that caused the complex to elute earlier than expected from the sepharose column. The
importance of this 2:1 stoichiometry in mediating the interaction with the type III
secretion apparatus is not III understood, but it is certainly an area worth investigating
considering both Class II and Class III chaperones also form dimers to interact with their
substrates[153]. The conservation of this chaperone dimer/substrate complex among
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bacterial type III secretion systems has led to the conclusion that this complex forms a
three dimensional secretion signal that directs it to the type III apparatus [151].
A three-dimensional secretion signal that could trigger recognition by the type III
A TPase has been proposed multiple times, but only a recent study was able to
demonstrate the role of a chaperone-mediated translocation signal. The type III effector
YopE from Yersinia pseudotuberculosis was dependent on a solvent exposed patch
corresponding to the chaperone-binding domain for translocation, but interestingly these
solvent exposed residues were not essential for chaperone binding[158]. This finding
indicated that the type III chaperone orders the chaperone-binding domain of the effector
such that a second secretion signal is exposed on the effector surface. Further work with
type III chaperone-effector complexes that have been previously crystallized will indicate
if the chaperone-mediated solvent-exposed patch is the universal three-dimensional
translocation signal.
Considering that Chlamydia has two possible type III ATPases (CdsN and FliA)
that are expressed during infection, it is probable that there is a difference in effector
recognition between these A TPases[35]. Whether these A TPases (or possibly
combinations of cytoplasmic type III components) would be able to differentiate between
N -terminal secretion signals (S 1) and/or chaperone-mediated translocation signals (S2) is
yet to be determined. Thus future experiments testing the interaction of alternate
chlamydial A TPases with chaperone-substrate complexes in vitro and in heterologous
systems will be revealing as to the importance of different secretion signals in type III
effector recognition, as well as clue us in to possible ATPase switching during actual
infection. Speculation about ATPase switching may seem far-fetched when considering
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the complete lack of precedence in other known bacterial type III secretion systems.
However since the chlamydial type III secretion systems have evolved in isolation from
the Proteobacteria for more than 2 billion years there will almost certainly be
Chlamydia-specific type III interactions and functions that are not present in the other

gram-negative type III secretion systems[22].

Roles for chaperone-effector interactions in developmental cycle regulation
As mediators of translocation type III chaperones may play an important role in
the regulation of the EB to RB and/or RB to EB transitions that are necessary for
establishing infection and spreading to surrounding tissues. Release of an effector, such
as TARP, may allow for interaction of its cognate chaperone, Slc 1, with another effector,
whose translocation could trigger post-invasion events. Such an ordered process could
conceivably be maintained by the specificity of the effectors' chaperone binding domain
for a specific chaperone dimer. CesT for instance, in EPEC, is known to act as chaperone
for multiple effectors, having the highest affinity for the invasion-associated effector Tir,
which is also the first of its cognate effectors to be detected in the host cell[159].
The apparent interaction of the chlamydial chaperone Slc2 (CT663) with both
E.coli RNA polymerase (RNAP) and the chlamydial major sigma factor a 66 indicates a

possible regulatory role for type III chaperones[159]. It is tempting to speculate that the
Slc2 interaction with a 66 of the chlamydial RNAP holoenzyme allows for subsequent
gene transcription by the alternate sigma factor a28, possibly initiating transcription of a
set of genes involved in the RB to EB differentiation or maintaining the persistent RB.
Both CT663 and the a28 -encoding gene fliA are mid-cycle genes and therefore their
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expressed products are likely to playa role in late developmental cycle events[93]. The
Slc2-Scc 1 interaction detected in two-hybrid studies may sequester Slc2 and prevent it
from acting as an anti-sigma factor during specific stages of infection. Determination of
Scc l' s cognate effector or function during infection may provide insight into how and
when Slc2 could act to regulate transcription. However, this area definitely needs to be
further investigated to really determine the importance of Slc2 in gene regulation.

Dependence of TARP's translocation on SlcJ in heterologous systems
While our biochemical assays only serve to indicate protein-protein interactions
between putative chlamydial type III chaperones and between the chaperone SIc 1 and the
invasion-associated effector TARP, the findings beget many possible roles for these
interactions during infection. I contend that Slc l' s main role is to achieve translocation of
its cognate effector TARP and subsequently ensure the efficient uptake of Chlamydia by
non-phagocytic eukaryotes. Using several different heterologous bacterial type III
secretion systems I attempted to determine the chaperone requirement for TARP
translocation. Translocation of p-Iactamase fused effectors was reported by the cleavage
of a lipophilic p-Iactam ring-containing compound CCF21AM. Because excitation of the
cleaved and non-cleaved substrates at 410 nm produced emissions of alternate
fluorescence wavelengths (510 nm and 450 nm, respectively), I was able to accurately
measure TARP translocation into a population of HeLa cells by a ratio of fluorescence.
This CCF21AM based translocation assay has been widely used for detecting
translocation of type III and type IV secreted effectors by Shigella, Legionella,
Salmonella, Yersinia, E. coli, and Pseuodomonas[ 160-163].
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The reproducibility of this assay is based in the fact that total fluorescence is
measured from a population of infected HeLa cells, so as long the multiplicities of
infection are equal among compared samples, then the differences in substrate absorption
and number of cells in each III are cancelled out when the fluorescence ratios are
calculated. I was able to detect translocation of p-Iactamase-fused TARP by Yersinia

enterocolitica and the SPI-2 system of Salmonella typhimurium. Co-expression with its
cognate chaperone significantly increased TARP translocation by both species.
However, I was unable to detect any TARP translocation by enterropathogenic

E. coli or by the SPI -1 system of S. typhimurium, even in the presence of Slc 1. Secretion
or translocation of chlamydial type III effectors had been previously reported with the
SPI-I, SPI-2, and Y eneterocolitica type III systems, but not with EPEC. One possible
reason for the lack of TARP translocation by EPEC could be that its ATPase recognizes a
different N-terminal secretion signal. Alternatively, it could be that a chlamydial
chaperone-mediated three-dimensional secretion signal cannot be recognized by the
EPEC type III apparatus.
It has been previously shown that some chlamydial effectors are preferentially

translocated by the heterologous SPI-1 or SPI-2 type III secretion systems[43]. Similarly,
in our translocation assays I see a preference for translocation of TARP by the SPI -2
system. However, the fluorescence ratio had previously only been applied to measure the
translocation of effectors within a few hours of infection, and the SPI-2 secretion system
translocates effectors from its intracellular Salmonella containing vesicle between 6 and
10 hours post-infection[161]. I had to consider the possibility the some of the CCF21 AM
substrate was able to access the non-translocated p-Iactamase-fused effectors inside the
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intracellular Salmonella, thus leading to a background level of cleaved substrate in this
assay. SPI-2 translocation of ~-lactamase fused effectors had been demonstrated
previously but instead of calculating a fluorescence ratio, they observed blue and green
fluorescence by live-cell microscopy[159]. Their microscopy results revealed a low level
of conversion of the green to blue signal, but they were still able to obviously distinguish
between cells in which a

~-lactamase

fused effector had been translocated (blue) from

cells with no translocation (green). This background level of cleavage falsely skews the
fluorescence ratio to indicate translocation in the (Empty)

~-lactamase

vector only

negative control. However, I still believe that the elevated fluorescence ratio for TARP
in the presence of SIc1 is significantly higher than this background, indicating actual
chaperone-mediated translocation by the SPI-2 secretion system of S. typhimurium.
Secretion of TARP into media had been previously demonstrated by Y

pseudotuberculosis[42], and I was able to confirm Yersinia's ability to secrete TARP by
Y enterocolitica. However, TARP's translocation into eukaryotic cells had not
previously been tested, and even though TARP is secreted into media without a
chaperone, secretion and translocation of effectors by Yersinia has been shown to have
differential requirements for chaperones[62]. It has been shown that for Yersinia
effectors, the N-terminal secretion signal is sufficient for secretion into low-calcium
media, while translocation of effectors into host cells requires their cognate chaperones.
This dogma is in agreement with our findings that TARP is secreted into media similarly
to the positive control Yersinia effector YopH, but T ARP requires SIc 1 to be efficiently
translocated into host cells.
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I perfonned phylogenetic analysis of cytoplasmic type III flagellar and nonflagellar A TPases from C. trachomatis and c.pneumoniae in comparison with the SPI-I
and SPI-2 ATPases from S.typhimurium, EscN from EPEC, and YscN from Y

enterocolitica to assess whether the relatedness of A TPases could explain TARP
translocation differences. The chlamydial non-flagellar ATPase CdsN was more closely
related to YscN than InvC, SsaN, or EscN. This finding agrees with the fact that

Yenterocolitica was able to secrete and translocate TARP. The SIc I-dependence of
TARP for efficient translocation of Yersinia indicates that the SIc 1: TARP complex
interacts with YscN in much the same way as it interacts with CdsN during chlamydial
infection. Since TARP is capable of being translocated by the Salmonella SPI-2 type III
secretion system but not by the SPI -1 system, it was interesting to note that the SPI -2
ATPase ssaN was more closely related to CdsN than the SPI -1 ATPase InvC. These
phylogenetic comparisons of type III A TPases imply that the SIc 1: TARP complex is also
likely to be able to interact with chlamydial CdsN. The agreement between ATPase
phylogeny and functional interaction with the effector TARP gives credibility to our
heterologous translocation assays.
Taken together, these findings indicate a role for SIc 1 in the translocation of
TARP by the chlamydial type III secretion apparatus (Figure 38).
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Figure 38. Model of Slcl-mediated translocation of T ARP into eukaryotic cells.
In the chlamydial EB , SIc1 associates with the N-terminus of TARP to reorganize its
chaperone binding domain, which in tum is recognized by the type III secretion
apparatus. Further unfolding by the ATPase allows TARP translocation through the type
III secretion apparatus and into the eukaryotic cytosol where molecules of TARP form
aggregates. Multiple domains on TARP are involved in actin polymerization that
facilitates invasion of eukaryotic cells. TARP aggregates are nucleate actin at their
WH2-like domains, while the tyrosine rich repeats become phosphorylated by host
kinases. These phosphorylate repeats act as magnets for host signaling molecules and
recruit further kinases guanine exchange factors that are involved in Rac activation and
subsequent Arp2/3 formation.
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CONCLUSIONS
This dissertation presents the first indication of a type III secretion chaperone
mediating the translocation of a chlamydial effector into the cytosol of its target host cell.
Importantly, this translocated effector, TARP, has been shown to be essential for
ensuring the efficient invasion of non-phagocytic cells and subsequently enabling

Chlamydia to propagate. Not only does the requirement of the chaperone SIcI in TARP
translocation indicate a similar mechanism of effector translocation as detected in other
type III-containing organisms, it also reveals the function of a previously uncharacterized
protein, which is not an easy feat considering the genetically-intractable nature of

Chlamydia spp.
Biochemical characterization of the specific interaction between SIc 1 and TARP
indicate a chaperone-mediated translocation signal that is likely recognized by a type III
A TPase. Detection of this translocation by the heterologous Salmonella SPI -2 and Y

enterocolitica type III secretion systems but not by enterropathogenic E.coli or the
Salmonella SPI-1 systems reveals a common mechanism for the chaperone-effector
recognition by type III components. Comparison of the A TPases between these species
indicates a role for the chlamydial ATPase CdsN in recognition of the SIc 1: TARP
complex. Further characterization the interaction of CdsN with this complex as well as
other type III chaperone: substrate complexes may define a mechanism of differential
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selection of type III substrates for translocation such as the recognition of threedimensional chaperone-substrate translocation signals.
Recent work has demonstrated the inhibition of chlamydial growth and division
by chemical inhibitors of type III secretion. The exact mechanism of this inhibition is
unknown, and a likely target of these and future inhibition studies is the type III ATPase.
Mapping the specific interactions that direct substrate recognition in the presence and
absence of the type III chaperones will be pivotal to guiding the design of type III
inhibitors for basic research and possibly for antibiotic use against several gram-negative
pathogens.
The conservation of the type III secretion system among distantly related
pathogenic and environmental Chlamydiaceae, all of which exhibit the biphasic
intracellular lifestyle, indicates a role for the type III secretion system in maintaining this
common lifestyle. Type III inhibitor studies will also provide valuable insight in the
mechanisms directing the regulation of the Chlamydia'S unique biphasic developmental
cycle. Substrate-switching, chaperone-mediated translocation hierarchies, interaction of
type III components with transcription machinery, and sequestering of type III
chaperones or substrates are all potential mechanisms that Chlamydia spp. may exploit to
ensure efficient survival and transitioning between infectious (EB) and replicating (RB)
forms.
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